 
Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE 
for Treatment of Acute Pulmonary Embolism 
PROTOCOL NUMBER: 2021 -EVT -01 
[STUDY_ID_REMOVED] 
DATE: July 18, 2023 
Version  Number:  5.1 
Version  Date:  07/18/23 
1 
CONFIDENTIAL   
    
 
  
 
Evaluating  the Safety  and Efficacy  of the AlphaVac  Multipurpose  Mechanical  
Aspiration (MMA) F1885 PE for Treatment of Acute  Pulmonary  Embolism  
 
 
PROTOCOL NUMBER: 2021 -EVT-01  
 
IDE NUMBER: G210308  
 
SPONSOR: ANGIODYNAMICS, INC.  
 
VERSION NUMBER: 5.1 
 
DATE: July 18 , 2023  
 
 
SPONSOR  CONTACT  PERSON:   LIZ MANNING , DIRECTOR, CLINICAL AFFAIRS  
 
 
 
 
 
This study  will be conducted  in accordance  with  Good  Clinical  Practices  (GCP  and ISO 14155)  and 
applicable  regulatory  requirements,  including  the archiving  of essential  documents.  
All unpublished  information  contained  within  this plan  is confidential  and the sole property  of 
AngioDynamics.  
 
 
 
 
 
 
*AngioDynamics, the AngioDynamics logo, and  AlphaVac  are trademarks and/or   registered  
trademarks  of AngioDynamics,  Inc.,  an affiliate  or subsidiary.  All other  trademarks  are property  
of their  respective owners.  © 2021 AngioDynamics,  Inc. 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
2 
CONFIDENTIAL   
  
 
APPROVAL  SIGNATURES  
 
CLINICAL INVESTIGATION  PLAN  NUMBER:  2021 -EVT-01 
CLINICAL  INVESTIGATION  PLAN  TITLE:   
 Evaluating  the Safety  and Efficacy  of the AlphaVac  
Multipurpose Mechanical Aspiration (MMA)  F1885 PE for 
Treatment of Acute Pulmonary  Embolism  
 
I, the undersigned,  have  read  this clinical  investigation  plan  and confirm  that to the best  of my knowledge  it 
accurately  describes the  planned  conduct  of the study.  
Juan Carlos Serna  
Sr VP, Scientific and Clinical Affairs  
AngioDynamics, Inc.  Date  
 Venkat Shankarraman  
 Manager, Medical Science Liaison  
 AngioDynamics, Inc.  Date  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
7/24/2023
7/24/2023
Version  Number:  5.1 
Version  Date:  07/18/23 
3 
CONFIDENTIAL   
  
SUMMARY  OF CHANGES  
 
Date  Version  Changes since last version  
July 18, 2023  5.1 1. Administrative update to specify that IDE progress reports will be 
submitted to FDA at 6-month intervals  
June 13 , 2023  5.0 1. Minor formatting updates throughout  
2. Updated number of sites to 30  
3. Updated the 30 -day follow -up visit to include the option of a virtual visit 
in the entire document  
4. Removed references to device accountability  
5. Added a Per Protocol analysis population  
6. Updated Primary Efficacy Endpoint to specify that all CTA data will be 
read centrally by the core lab.  
August 15, 2022  4.0 1. Updated version number from 3.0 to version 4.0 in the entire document  
2. Included Pericardial Effusion, Cardiac arrest,  Pulmonary Artery 
Injury/Wire Perforation,  and Hemothorax as an adverse event in section 
10.11 and Appendix I  
3. Updated index procedure to Day  1 from Day 0 in section 8.2 (Study 
Visits)  
February 22, 
2022  3.0 1. Updated version number from 2.0 to version 3.0 in the entire document  
2. Updated the definition of the ‘As Treated’ population to include 
patients in whom the device was introduced in the entire document  
3. Table 5 in section 10.1 (Adverse Events) was revised to include grade 5 
in the adverse event severity scale  
4. Corrected cannula description to include 18F in section 5.2F.2  
5. Section 10.5 now provides and option of emailing the sponsor  
6. Added ‘ Important medical event’ as one of the SAEs in section 10.1.1  
7. Information on handling missing data in section 11.7 was updated to 
include efforts that would be made to minimize missed visits and drop -
outs along with a discussion on expected percentage of m issing data  
8. Updated section 11.4.2 on the null hypothesis and alternative 
hypothesis  for the primary safety endpoint,  to change the directionality 
of the hypotheses (i.e., H 0: MAE < 0.25 changed to H 0: MAE > 0.25 and 
H1: MAE ≥ 0.25 changed to H 1: MAE ≤ 0.2 5) 
9. Added section 11.8 and section 11.9 to provide additional information 
on sensitivity analysis and poolability of data  
10. Formatting edits were made throughout the document (font, 
numbering, alignment)  
September 3, 
2021  2.0 1. Updated version number from 1.0 to version 2.0 in the entire document  
2. Updated product name from Alpha Vac MMA System to AlphaVac  
Multipurpose Mechanical Aspiration (MMA) F1885 PE in the entire 
document  
3. Updated sample size of the study to enroll 122 patients  in (Section 7: 
Study Design and Section 11: Statistical considerations)  
4. Updated Section 2 to include an enrollment CAP of 24 patients per site  
5. Added a secondary endpoint that will evaluate the change in modified 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
4 
CONFIDENTIAL   
 miller index between baseline and 48 hours post procedure by CT A 
(Section 2: Protocol Summary and Section 6.4)  
6. Added  an Exploratory endpoint to access the health -related social 
needs  during the patient’s  baseline visit  (Section 2: Protocol Summary 
and Section 6.4 and Section 11.4.5)  
7. Included section 14.8.1: Impact on Medicare Beneficiaries  
8. Revised the ITT and MITT terms to  “as treated ” and “Modified as 
treated populations ” for the primary analys is, respectively in the entire 
document  
9. Updated “as treated” and “modifies as treated” def initions (Section 2: 
Primary Analysis Summary) and Section 11.3 (Analysis Population)  
10. Minor update to Section 10.11 (Risk Benefit analysis)  
11. Updated Section 11 (statistical analysis) to include the SAS code  
12. Added Hemoptysis, Intrapulmonary or intrapleural  hemorrhage under 
pulmonary vascular injury (Appendix I: Study Definitions)  
13. Minor formatting edits throughout the document  
14. Updated the list of abbreviations  
15. Updated References  
 
 
 
LIST OF ABBREVIATIONS  
 
ADE Adverse  Device  Effect  
AE Adverse  Event  
AHA  American  Heart  Association  
AHC HRSN  Accountable Health Communities Health -Related Social needs Screening 
Tool  
BL Baseline  
BPM  Beats  Per Minute  
CDT Catheter  Directed  Therapy  
CEC Clinical  Events  Committee  
CFR Code  of Federal  Regulations  
CRO  Contract  Research  Organization  
CRF Case  Report  Form  
CI Confidence  Interval  
CIP Clinical  Investigational  Plan  
CT Scan  Computed  Tomography  Scan  
CTA Computed  Tomography  Angiography  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
5 
CONFIDENTIAL   
 CTCAE  Common  Terminology  Criteria  for Adverse  Events  
CV Curriculum  Vitae  
d Day 
DEI Data  Element Identifier  
DMC  Data  Monitoring  Committee  
ECMO  Extracorporeal  membrane  oxygenation  
EDC Electronic  Data  Capture  
EA Efficacy  Analysis  
eCRF  Electronic  Case  Report  Form  
EMR  Electronic  Medical  Record  
FDA U.S. Food  and Drug  Administration  
FU Follow  up 
GCP Good  Clinical Practice  
HIPAA  Health  Insurance  Portability  and Accountability  Act of 1996  
HIT Heparin  Induced  thrombocytopenia  
ICF Informed  Consent  Form  
ICH International  Committee  on Harmonization  
IDE Investigational  Device  Exemption  
IFU Instructions  for Use 
IRB Institutional  Review  Board  
IRE Irreversible  Electroporation  
ISO International  Organization  for Standardization  
ISS Injury  Severity  Score  
LOS Length  of Hospital  Stay  
LPM  Liters  per minute  
LTFU  Lost to follow  up 
LV Left Ventricle  
m Month  
MAE  Major  Adverse  Events  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
6 
CONFIDENTIAL   
 MMA  Manual  Mechanical  Aspiration  
MRI Magnetic  Resonance  Imaging  
PAP Pulmonary  Artery  Pressure  
PE Pulmonary  Embolism  
PI Principal  Investigator  
PMT  Percutaneous  Mechanical  thrombectomy  
PPMAE  Peri-Procedural  Major  Adverse  Events  
QC Quality  Control  
RCT Randomized  Clinical  Trial  
RV Right  Ventricle  
SAE Serious  Adverse  Event  
SADE  Serious  Adverse  Device  Effect  
SAP Statistical  Analysis  Plan  
SBP Systolic  Blood  Pressure  
SD Standard  Deviation  
SDV Source  Data  Verification  
SIV Site Initiation  Visit  
SN Serial  number  
SOC Standard  of Care  
SOP Standard  Operating  Procedure  
tPA Tissue -plasminogen  activator  
w Week  
y Year  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
7 
CONFIDENTIAL   
 Table of Contents  
1 STATEMENT  OF COMPLIANCE  ................................ ................................ ................................ .......  11 
2 PROTOCOL  SUMMARY  ................................ ................................ ................................ .................  12 
3 STUDY  SCHEMA  ................................ ................................ ................................ ...........................  16 
4 SCHEDULE  OF ACTIVITIES  ................................ ................................ ................................ ..............  17 
5 INTROD UCTION  TO THE CLINICAL  STUDY  ................................ ................................ ......................  18 
5.1 BACKGROUND  ................................ ................................ ................................ .............................  18 
5.1.1  JUSTIFICATION  FOR THE CLINICAL  INVESTIGATION  ................................ ................................ ........  18 
5.2 DESCRIPTION  OF THE DEVICE  ................................ ................................ ................................ ........  19 
5.2.1  GENERAL  DEVICE  DESCRIPTION  ................................ ................................ ................................ .... 19 
5.2.2  CANNULA  DESCRIPTION  ................................ ................................ ................................ ...............  19 
5.2.3  SHEATH  DESCRIPTION  ................................ ................................ ................................ ..................  19 
5.2.4  OBTURATOR  DESCRIPTION  ................................ ................................ ................................ ...........  20 
5.2.5  ASPIRATOR  HANDLE  DESCRIPTION  ................................ ................................ ...............................  20 
5.2.6  WASTE  BAG  DESCRIPTION  ................................ ................................ ................................ ............  20 
5.3 MECHANISM  OF ACTION  FOR THE ALPHAVAC  MMA  F1885 PE ................................ ........................  20 
6 CLINICAL  STUDY  PURPOSE  AND  ENDPOINT  ................................ ................................ ...................  21 
6.1 OBJECTIVE  ................................ ................................ ................................ ................................ ... 21 
6.2 PRIMARY  SAFETY  AND  EFFICACY  ................................ ................................ ................................ .. 21 
6.3 SECONDARY  ENDPOINTS  ................................ ................................ ................................ ..............  21 
6.4 EXPLORATORY  ENDPOINT  ................................ ................................ ................................ ............  22 
7 STUDY DESIGN  ................................ ................................ ................................ .............................  22 
7.1 STUDY  DESCRIPTION  ................................ ................................ ................................ ....................  22 
7.2 STUDY  POPULATION  ................................ ................................ ................................ ....................  22 
7.2.1  INCLUS ION CRITERIA  ................................ ................................ ................................ ....................  22 
7.2.2  EXCLUSION  CRITERIA  ................................ ................................ ................................ ....................  23 
7.3 STUDY  ENROLLMENT  ................................ ................................ ................................ ....................  23 
7.3.1  ENROLLMENT  PROCEDURE  ................................ ................................ ................................ ...........  24 
8 STUDY  PROCEDURES  ................................ ................................ ................................ ....................  25 
8.1 STUDY  PROCEDURES  ................................ ................................ ................................ ....................  25 
8.2 STUDY  VISITS  ................................ ................................ ................................ ...............................  25 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
8 
CONFIDENTIAL   
 8.3 ADJUNCTIVE  TREATMENTS  ................................ ................................ ................................ ...........  26 
9 PARTICIPANT  DISCONTINUATION/WITHDRAWAL  ................................ ................................ .........  26 
9.1 PARTICIPANT  WITHDRAWAL  ................................ ................................ ................................ ........  26 
9.2 TERMINATION  OF PATIENT  PARTICIPATION  ................................ ................................ ..................  26 
9.3 SCREEN  FAILURE  ................................ ................................ ................................ ..........................  26 
9.4 LOST TO  FOLLOW -UP................................ ................................ ................................ ....................  27 
10 STUDY  ASSESSMENTS  AND ADVERSE EVENT  REPORTING  ................................ ..............................  27 
10.1  ADVERSE  EVENTS  ................................ ................................ ................................ .........................  27 
10.1.1  DEFINIT ION OF SERIOUS  ADVERSE EVENT  (SAE)  ................................ ................................ ............  29 
10.2  ADVERSE  DEVICE  EFFECTS  ................................ ................................ ................................ ............  29 
10.3  UNANTICIPATED  ADVERSE  DEVICE  EFFECTS  (UADE)  ................................ ................................ ...... 29 
10.4  RELATIONSHIP  TO STUDY DEVICE:  ................................ ................................ ................................  30 
10.5  DEATH  NOTICE  ................................ ................................ ................................ .............................  31 
10.6  DEVICE  COMPLAINT  AND  MALFUNCTION  ................................ ................................ .....................  31 
10.7  MEDICAL  MONITORING  ................................ ................................ ................................ ................  32 
10.8  HANDLING  AND REPORTING  SAFETY EVENTS  ................................ ................................ ................  32 
10.9  DATA  MONITORING  COMMITTEE (DMC)  ................................ ................................ .......................  32 
10.10  CLINICAL  ENDPOINT  ADJUDICATION  COMMITTEE  (CEC)  ................................ ................................  33 
10.11  RISK  BENEFIT  ANALYSIS  ................................ ................................ ................................ ................  33 
11 STATISTICAL  CONSIDERATIONS  ................................ ................................ ................................ ..... 35 
11.1  GENERAL  CONSIDERATIONS  ................................ ................................ ................................ .........  35 
11.2  DETERMINATION  OF SAMPLE  SIZE  ................................ ................................ ................................  35 
11.3  ANALYSIS  POPULATION  ................................ ................................ ................................ ................  37 
11.3.1  AS TREATED POPULATION  ................................ ................................ ................................ ............  37 
11.3.2  MODIFIED  AS TREATED POPULATION  ................................ ................................ ...........................  37 
11.4  STUDY  ENDPOINT ANALYSIS  ................................ ................................ ................................ .........  38 
11.4.1  PRIMARY  EFFICACY  ENDPOINT  ANALYSIS  ................................ ................................ ......................  38 
11.4.2  PRIMARY  SAFETY  ENDPOINT ANALYSIS  ................................ ................................ .........................  38 
11.4.3  SECONDARY  EFFICACY  ENDPOINT  ANALYSIS  ................................ ................................ .................  39 
11.4.4  SECONDARY  SAFETY  ENDPOINT  ANALYSIS  ................................ ................................ ....................  39 
11.4.5  EXPLORATORY ENDPOINT  ANALYSIS  ................................ ................................ .............................  39 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
9 
CONFIDENTIAL   
 11.4.6  SUBGROUP  ANALYSIS  ................................ ................................ ................................ ...................  39 
11.5  ADVERSE  EVENT  ANALYSIS  ................................ ................................ ................................ ...........  40 
11.6  PROTOCOL  DEVIATIONS  ................................ ................................ ................................ ...............  40 
11.7  HANDLING  MISSING  DATA  ................................ ................................ ................................ ...........  40 
11.8  SENSITIVITY ANALYSES  ................................ ................................ .........  Error! Bookmark not defined.  
11.9  POOLABILITY OF DATA  ................................ ................................ ................................ .................  41 
12 DATA  QUALITY  ASSURANCE  ................................ ................................ ................................ .........  42 
12.1  DATA  MANAGEMENT  ................................ ................................ ................................ ...................  42 
12.2  CONFIDE NTIALITY  OF DATA  ................................ ................................ ................................ ..........  43 
12.3  SOURCE  DOCUMENTS  ................................ ................................ ................................ ..................  43 
12.4  ELECTRO NIC CASE  REPORT  FORMS ................................ ................................ ................................  44 
12.5  RECORD RETENTION  ................................ ................................ ................................ .....................  44 
12.6  CLINICA L DATA  MONITORING  PROCEDURES  ................................ ................................ .................  45 
13 INVESTIGATOR  AND  SPONSOR  RESPONSIBILITIES ................................ ................................ ..........  45 
13.1  INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ................................ . 45 
13.1.1  DEVIATIONS  FROM  INVESTIGATIONAL  PLAN  ................................ ................................ .................  46 
13.1.2  MAINTAINING  RECORDS  ................................ ................................ ................................ ..............  47 
13.1.3  SUBMITTING  REPORTS  ................................ ................................ ................................ .................  48 
13.2  SPONSOR  RESPONSIBILITIES  ................................ ................................ ................................ .........  48 
13.2.1  GENERAL  DUTIES  ................................ ................................ ................................ ..........................  48 
13.2.2  SELEC TION  OF INVESTIGATORS  ................................ ................................ ................................ ..... 48 
13.2.3  TRAINING  ................................ ................................ ................................ ................................ .... 49 
13.2.4  CHANGES  IN THE CLINICAL  INVESTIGATIONAL  PLAN  ................................ ................................ ...... 49 
13.2.5  WITHDRAWAL  OF FOOD  AND  DRUG  ADMINISTRATION  APPROVAL  ................................ ...............  50 
14 ETHICS  AND  REGULATORY  COMPLIANCE  ................................ ................................ .......................  50 
14.1  CONDUCT OF  THE CLINICAL  STUDY  ................................ ................................ ...............................  50 
14.2  CONFLICT  OF INTEREST  ................................ ................................ ................................ .................  50 
14.3  INSTITUTIONAL  REVIEW  BOARD  ................................ ................................ ................................ ... 50 
14.4  CLINICAL  STUDY  INFORMED  CONSENT  APPROVAL  ................................ ................................ ........  51 
14.5  SUBJECT  IDENTIFICATION  AND  CONFIDENTIALITY  ................................ ................................ .........  51 
14.6  SITE  QUALIFICATION  VISIT  ................................ ................................ ................................ ............  51 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
10 
CONFIDENTIAL   
 14.7  SITE INITIATION  VISIT  ................................ ................................ ................................ ...................  51 
14.8  INSURANCE  ................................ ................................ ................................ ................................ .. 52 
14.8.1  IMPACT ON M EDICARE BENEFICIARIES  ................................ ................................ .........................  52 
14.9  SITE AUDITS  ................................ ................................ ................................ ................................ . 52 
14.9.1  INTERNAL  AUDITS  BY SPONSOR  OR SPONSOR’S  DESIGNEE  ................................ ............................  53 
14.10  EXTERNAL  AUDITS  ................................ ................................ ................................ ........................  53 
14.11  PUBLIC  DOMAIN ACCESS  TO THE CLINICAL  STUDY  ................................ ................................ .........  53 
15. GENERAL  CONSIDERATIONS  ................................ ................................ ................................ .........  53 
15.1  DISCONTINUATION  OF THE STUDY  ................................ ................................ ...............................  53 
15.2  USE OF INFORMATION  AND  PUBLICATIONS  ................................ ................................ ..................  53 
16. APPENDIX I: STUDY  DEFINITIONS ................................ ................................ ................................ .. 55 
17 REFERENCES  ................................ ................................ ................................ ................................ . 58 
18 ATTACHMENTS  ................................ ................................ ................................ ............................  60 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
11 
CONFIDENTIAL   
 1 STATEMENT  OF COMPLIANCE  
 
The study will be conducted in compliance with the US FDA Title 21 CFR Part 50 – Protection of Human  
Patients and Part 56 – Institu tional Review Boards and Part 812 – Investigational Device Exemption; the  
International Council for Harmonisation for Pharmaceuticals for Human Use (ICH) GCP guidelines E6R2 ;  
the Belmont Report; US Title 45 CFR Part 164 Subpart E – Privacy of Individually  Identifiable Health  
Information and the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule; and any  
applicable  national guidelines.  
 
The protocol, informed consent form(s), recruitment materials, and all participant’s materials will be  
submitted to the Food and Drug Administration (FDA), Institutional Review Board (IRB) for review and  
approval.  Approval of both the protocol and the consent form must be obtained before a participating  
site may enroll participants. Any am endment to the protocol will require review and approval by the IRB  
before the changes are implemented to the study.  In addition, all changes to the consent form will be  
IRB-approved;  a determination  will be made  regarding  whether  a new  consent  needs  to be obtained  from  
participants  who  provided  consent, using  a previously approved  consent  form.  
 
The Principal Investigator will assure that no deviation from, or changes to the protocol will take place  
without prior agreement from the Investigational Device Exemption (IDE) sponsor and documented  
approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate  
hazard(s)  to the trial participants.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
12 
CONFIDENTIAL   
  
2 PROTOCOL  SUMMARY  
 
STUDY  TITLE:  Evaluati ng the Safety  and Efficacy  of the AlphaVac  Multipurpose  Mechanical  Aspiration  
(MMA) F1885 PE for Treatment  of Acute  Pulmonary  Embolism  
DEVICE  NAME:  AlphaVac  Multipurpose  Mechanical  Aspiration  (MMA)  F1885 PE 
DEVICE  DESCRIPTION:  The AngioDynamics’ AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has  
five main components, a flexible cannula (F1885), sheath, tapered obturator, aspirator  
handle,  and waste bag.  
 
The AlphaVac MMA F1885 PE is a mechanical aspiration thrombectomy  device with a 
nitinol basket reinforced, self -expandable funnel shaped distal tip, that is  collapsed  using  
an over -sheath  that is advanced  though  a 22 Fr sheath  and over  a guidewire  into the 
venous  system  percutaneously.  
  
INDICATION  FOR USE:  The Cannula  is indicated  for 
• The non-surgical  removal  of thrombi or  emboli  from  vasculature  
• Aspiration  of contrast media  and other  fluids  into or from  vasculature  
 
The Cannula  is intended  for use in the venous  system  and for the treatment  of 
pulmonary embolism.  
The Aspirator  Handle  is indicated  as a vacuum  source  for the AlphaVac  MMA  System.  
MANUFACTURER:  AngioDynamics,  Inc. 
SPONSOR:  AngioDynamics,  Inc. 
REGULATORY  STATUS:  Proposed  Investigational  Device  Use 
STUDY  PURPOSE:  To evaluate  the safety  and effectiveness  of percutaneous  mechanical  aspiration  
thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE 
in a prospective  trial of patients  with  acute  intermediate -risk pulmonary  embolism  (PE).  
STUDY  DESCRIPTION:  AngioDynamics’  prospective,  single -arm,  multicenter  Investigational  Device  Exemption  
(IDE)  study.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
13 
CONFIDENTIAL   
 ENDPOINTS:  Primary  Endpoints:  
• Primary  efficacy  endpoint  
o Reduction  in RV/LV  ratio between  baseline  and 48 hours  post  procedure  
assessed  by CTA.  All CTA data will be read centrally by the core lab.  
• Primary  safety  endpoint  
o The rate of Major  Adverse  Events  (MAEs)  within  the first 48 hours  after  
the index  procedure.  
The MAEs  include:  
▪ Device -related  death  
▪ Major  bleeding  
▪ Device -related  SAEs  which  includes:  
• Clinical  Deterioration  
• Pulmonary  Vascular  Injury  
• Cardiac  Injury  
 
Secondary  endpoints:  
• Secondary  efficacy  endpoints:  
o Use of thrombolytics  within  48 hours of  the procedure.  
o Length  of stay in the Intensive  care  unit (ICU)/Hospital  within  30 days  post - 
procedure.  
o Change in Modified Miller Index between  baseline  and 48 hours  post  
procedure assessed  by CTA.  
• Secondary  safety  endpoints:  
o Rate  of device  related  complications  including  clinical  deterioration,  
cardiac  injury,  pulmonary  vascular injury,  major  bleeding,  and device - 
related  death  within  48 hours  of the index  procedure.  
o Rate of device -related Serious Adverse Events (SAEs) and death for any - 
cause  within  30 days  post  procedure.  
o Symptomatic  PE recurrence  within  30 days.  
Refer  Appendix  I for study  definitions.  
EXPLORATORY ENDPOINT:  This study will collect baseline data to 
identify unmet social needs such as housing instability, violence, 
financial strain, etc. Exploratory analysis may be conducte d to evaluate 
unmet healthcare needs with study enrollments and outcomes.  
 
STUDY  POPULATION:  Patients  with  acute  intermediate -risk Pulmonary  Embolism.  
 
Inclusion  Criteria  
A potential  subject  will be included  in the study  if he/she  meets  all the following  
inclusion  criteria:  
1. Provision  of signed  and dated  informed  consent  form.  
2. Subject is  18 years  of age and older.  
3. Subject presents clinical signs and symptoms consistent with acute  
intermediate -risk pulmonary  embolism  for less than  or equal  to 14 days.  
4. Subject  has a diagnosis  of pulmonary  embolism  detected  from  computed  
tomography  angiography  (CTA).  
5. Subject  has a RV/LV  ratio  of 0.9 or higher.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
14 
CONFIDENTIAL   
 6. Subject  has a systolic  blood  pressure  (SBP)  of 90mmHg  or higher  
7. Subject  has a heart rate  of 130 beats  per minute  (BPM)  or less prior  to the 
procedure.  
8. Subject  is deemed  medically  eligible  for interventional  procedure(s)  per 
institutional  guidelines and/or  clinical  judgment.  
 
Exclusion  Criteria  
A potential  subject  will be excluded  from  the study  if he/she  meets  any of the following  
exclusion  criteria:  
1. Subjects  who  are or may  be pregnant  as determined  by a positive  pregnancy  test or 
who  are breastfeeding.  
2. Subjects  who  have  any contraindication  to systemic  or therapeutic  doses  of heparin  
or anticoagulants.  
3. Subjects  who  have  used  thrombolytics  (tPA)  in the past  30 days  of baseline  CTA.  
4. Subjects  who  have  pulmonary  hypertension  with  peak  pulmonary  artery  pressure  
(PAP)  > 70  mmHg.  
5. FiO2  requirement  >40%  or >6 LPM to  keep  oxygen  saturations  >90%  
6. Subjects  with  hematocrit <28%  within  6 hours  of index  procedure.  
7. Subjects  with  platelets  count  < 100,000/µL.  
8. Subjects  with  serum  creatinine  >1.8  mg/dL.  
9. Subjects  with  International  Normalized  Ratio  (INR)  > 3 
10. Subjects who  have  undergone  a major  trauma  within  the past  14 days  of the  index  
procedure  and have Injury  Severity Score (ISS)  > 15.  
11. Subjects  with  the presence  of cancer  requiring  active  chemotherapy.  
12. Subjects  with  known  bleeding diathesis  or coagulation  disorder.  
13. Subjects  who  have  had a cardiovascular  or pulmonary  surgery  within  the past  7 days  of 
index  procedure.  
14. Subjects  with  a history  of severe  or chronic  pulmonary  hypertension,  
uncompensated heart  failure,  chest  irradiation,  underlying  lung disease  that is 
oxygen dependent, Heparin - induced thrombocytopenia (HIT) and/or chronic left  
heart disease with  left ventricular  ejection  fraction ≤ 30%.  
15. Subjects with known anaphylactic reaction to radiographic contrast agents that  
cannot be  pretreated.  
16. Subject  requires  Vasopressor  after fluids  to keep pressure  ≥ 90mmHg.  
17. Subjects  with  left bundle  branch  block.  
18. Subjects  who  have  intracardiac  lead  in the right  ventricle  or atrium.  
19. Evidence such as imaging or other that suggest the subject is not appropriate for  this 
procedure.  
20. Subjects  that have life  expectancy  < 90 days.  
21. Subjects  dependent  on extracorporeal  life support  such  as extracorporeal  membrane  
oxygenation  (ECMO).  
22. Participation  in another  investigational  study  
STUDY  CENTERS  & 
LOCATION:  The clinical  study  is to be conducted  at up to 30 investigative  sites  in the United  States.  
The investigative  sites  will consist  of hospitals.  
 
To reduce bias by sites, each site may enroll up to 24 eligible subjects  who have 
successfully completed their index procedure with the AlphaVac MMA F1885 PE. 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
15 
CONFIDENTIAL   
 DESCRIPTION OF  STUDY  
INTERVENTION:  The AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE has five main  
components,  a flexible  cannula  (F1885), sheath,  tapered  obturator,  aspirator,  and waste  
bag.  
The AlphaVac  MMA  F1885 PE is a mechanical  aspiration  thrombectomy  device with a 
nitinol basket reinforced, self -expandable funnel shaped distal tip, that is  collapsed using 
an over -sheath that is advanced though  a 22 Fr sheath and over a  guidewire  into the 
venous  system percutaneously.  
 
During use the cannula is placed within the jugular or one of the common femoral veins  
and connected to the aspirator handle. Once access is gained, the cannula is advanced  
under image guidance towards the undesirable intravascular (i.e., thrombus or emboli)  
until it is engaged, the aspirator is then pulled back creating suction pulling the material  
into the cannula,  removing  it from  the vasculature.  The aspirated  material  is then  moved  
from  the aspiration  handle  into the waste  bag for disposal.  
STUDY  DURATION:  Individual  study  participation:  Subjects  will be followed  for 30 days  post  index  procedure.  
 
Overall  study  duration:  Accrual  is estimated  to require  18 months  to complete,  and the 
study  will be  complete 30  days  after  the enrollment  of the last subject.  
SAMPLE SIZE  
STATISTICS:  For the purposes of assessing safety and effectiveness, a minimum of 122 subjects will be 
enrolled in the clinical study. This acc ounts for a 15% possible drop -out rate for subjects 
who will be lost to follow -up. 
 
PRIMARY ANALYSIS  
SUMMARY:  Analysis  Cohort s: 
• As Treated  population : This population includes all subjects who met the 
inclusion/exclusion criteria and in whom the F1885 cannula is placed within the 
jugular or one of the common femoral veins . 
• Modified As Treated  population : This population  includes  all subjects in the As 
Treated population who did not receive thrombolytics during the index procedure.  
• Per Protocol population: This population includes all subjects in the Modified As 
Treated population  who had no major protocol deviations.  
 
Analysis of  all efficacy  endpoints  will be performed  on the As Treated , Modified As 
Treated , and Per Protocol   population s, with  the Modified Ts Treated  population  serving  as 
the primary  analysis  cohort . Analysis  of all safety   endpoints  will be performed on  the As 
Treated  population . 
CORE LABORATORY:   An independent Core  Lab will review  imaging scans  in analysis  of RV/LV  diameter.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
16 
CONFIDENTIAL   
 3 STUDY  SCHEMA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mechanical  Aspiration  thrombectomy  using  the AlphaVac  Multipurpose  Mechanical  
Aspiration  (MMA)  F1885 PE 
Informed Consent and baseline data collection  
Hemodynamically stable with no vasopressor requirement  
Heart  rate <=130  beats/min  
Systolic  Blood  Pressure  ≥ 90 mmHg  
RV/LV  ratio  (based  on CTA)  of ≥ 0.9 
Subject Diagnosed with Symptomatic acute intermediate -risk pulmonary embolism in the  
last 14  days  and meets  all study  inclusion  criteria  
Death,  Discontinuation,  Loss  to follow  up, Study  End 
Data  Collection at 48 hours  and 30 days  post  index  procedure  
Primary  Efficacy  & Safety  endpoints  
1.Change  from  baseline  in RV/LV  ratio  
2.Rate  of Any Major  Adverse  Events  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
17 
CONFIDENTIAL   
  
4 SCHEDULE  OF ACTIVITIES  
Table  1. Schedule  of Events  for Screening,  Baseline  and Early  Follow -up Visits  
 
 
 
 
Study  assessment  
 
Screening  
 
Baseline/Procedure a 
(At 0 hours)  
48 -hours  (±6 Hour)  
Post -procedure  
Hospital  Discharge  
 
 
30- days (± 7 days)b 
Post -procedure  
Medical  history  and Demographics  X     
ACH - HRSN Screening Tool  f  X    
Vital  Signs  X X X X Xg 
Hematocrit/FiO 2/ Creatinine/  
Platelets/  INR/  Troponin  X  X   
CTA (RV/LV  Ratio)  X  X   
Pulmonary  Artery  Pressure  
(mmHg)   Xd    
Concomitant  Medications  e X X X X X 
Time  of Procedure   X    
Major/  Minor  Bleeding   X X X  
Pregnancy  Test  c X     
Hospital  Stay     X  
Adverse  Events   X X X X 
Symptomatic PE  Recurrence      X 
 
 
 
a) Procedure  is defined  as day zero  
b) 30 day follow  up begins from  procedure . This visit can optionally be completed virtually. However, if during the 
virtual visit, the site determines the patient should be seen in person, the subject will be asked to  come in for 
evaluation.  
c) Pregnancy test can be  from  urine  or blood test  
d) Pulmonar y pressures  will be obtained  pre- and post -procedure  
e) Concomitant  medications  include  anticoagulants,  vasopressors,  thrombolytics  used,  and all other  
medications  given  for AEs  and SAEs  during  the study  
f)  The Accountable Health Communities (ACH) Health -Related Social Needs (HRSN) Screening Tool1 
g) Vital Signs will be obtained if the patien t completes the 30-day follow up visit  in person  or if deemed 
necessary after the virtual visit. 
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
18 
CONFIDENTIAL   
 5 INTRODUCTION  TO THE CLINICAL  STUDY  
 
5.1 BACKGROUND  
Pulmonary Embolism (PE) represents the third leading cause of cardiovascular mortality.2 PE is 
thrombus  that traveled  and became  lodged  within  the pulmonary  arteries.  Pulmonary  emboli  usually  
arise  from  thrombi  that originate  in the deep  venous  system  of the lower  extremities;  however,  they  
also originate in the pelvic, renal, upper extremity veins, or the right heart chambers, though rarely.  
PE is commonly broken into three main categories: massive or hi gh risk, submassive or intermediate  
risk, and low risk.  The focus of this study is submassive or intermediate risk PE. Patients with  
intermediate risk PE typically have RV strain (RV/LV ratio ≥0.9) without hypertension, confirmed via  
imaging  (computed  tomo graphy  pulmonary  angiography)  and increased  cardiac  biomarkers  (i.e.,  
troponins  or brain  natriuretic  hormone).2 Patients  with  submassive  or intermediate - risk PE account 
for 35% to 55% of hospitalized patients with PE with a mortality rate of 5 -24%.2,4 For      such patients, 
therapies aim to avert possible hemodynamic collapse and death resulting from  progressive  right -
sided heart failure  and to expedite symptom  resolution.2 
 
The current standard of care treatment PE is therapeutic anticoagulation. Spe cific to patients with  
intermediate -risk PE the American  Heart  Association  (AHA)  discourages  the routine  administration  of 
thrombolytic  therapy  (either  systemic  or catheter  directed)  and recommends  that patients  should  be 
promptly  anticoagulated,  receive  supportive  measures  and be closely  monitored.2 However,  adverse  
outcomes,  despite  anticoagulation,  in patients  with  intermediate -risk PE has  prompted  physicians  to 
consider  therapeutic  escalation  through  systemic  thrombolysis,  catheter -directed  therapies,  or 
surgical  embolectomy.2 
 
AHA  states  that catheter -based  embolectomy  is an option  for patients  that remain  hemodynamically  
stable  and have  had an assessment  completed  to consider  factors  that elevated  risk of 
decompensation  with  an elevated  bleeding  risk, with  the caveat  that concerns  for procedural  
hemodynamic or  respiratory decompensation.2 
 
5.1.1 JUSTIFICATION  FOR  THE CLINICAL  INVESTIGATION  
 
A catheter directed therapy (CDT) that is gaining interest by physicians is percutaneous mechanical  
thrombectomy (PMT). PMT has been designed to clear large arteries and veins by removing the  
thrombus from the vasculature. Mechanical aspiration thrombectomy, a subset of PMT, utilizes a  
large  lumen  aspiration  catheter  that utilizes  manual  suction  to remove  the thrombus.  
While  there  is limited  data  available  for large -bore  thrombectomy  devices,  instances  of acute  
hemodynamic respiratory collapse as well as right -sided hear t and PA injury have been reported.2 
However, PMT has been found to be effective and safe for debulking of centrally located fresh  
thrombus,  lowering  PAP and improving  hemodynamics  and blood  oxygenation,  all of which  permits  a 
rapid  reversal  of right  ventri cle overload  with  a decrease  in the mortality  rate,  in patents  
contraindication  or unsuccessful pharmacological  fibrinolysis.5 
 
While  further  comparative  studies  comparing  currently  recommended  catheter -directed  and 
pharmacological approached are still required, PMT appears to be promising in the treatment of  
acute Pulmonary Embolism  (PE).2 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
19 
CONFIDENTIAL   
 At present, it is unknown if the catheter aspiration thrombectomy with AlphaVac Multipurpose  
Mechanical Aspiration (MMA) F1885 PE can safely and effectively improve patient  outcomes for 
patients with acute PE. This prospective, multicenter analysis will provide outcomes,  which will serve 
as preliminary data to plan to evaluate the use of AlphaVac MMA  F1885 PE in future studies.  
 
5.2 DESCRIPTION  OF THE DEVICE  
5.2.1 GENERAL  DEVICE  DESCRIPTION  
The device under clinical investigation is AlphaVac Multipurpose Mechanical Aspiration (MMA)  F1885 
PE which  consist  of five sterile  single  use main  components:  a flexible  aspiration  cannula  (F1885), 
sheath, obturator, aspirator, and a waste bag. All components are packed together as sterile single  
use device  by AngioDynamics  located  in Latham, NY  12110,  United States  (US).  
The AlphaVac  MMA  F1885 PE design allows for  the undesirable  intravascular  material  to compress  
into the cannula’s  inner  lumen  and be aspirated  from  the vasculature  and captured  in the waste  bag.  
 
5.2.2 CANNULA  DESCRIPTION  
The cannula large bore design ( 18F) and funnel shaped tip are intended to facilitate the removal of 
thrombus, embolus and clot during minimally invasive percutaneous procedures.  
The stainless -steel  wire  mid-wall reinforced  cannula  shaft  ensures  appropriate  stiffness  to resist  
kinking, collapse and deformation that may compromise the lumen and inhibit flow. Additionally, it  
is flexible  enough  to allow  the cannula  to be manipulated  through  the vasculature  utilizing  standard  
percutaneous  insertion  techniques.  The cannula  is provided  in an 85° angled  distal  end configuration  
with  a working  length  of 44.4  inches  and a nominal  diameter  of 18F.  
 
5.2.3 SHEATH  DESCRIPTION  
The sheath is used place the catheter within the target location, actuate the distal cannula funnel  
and alter  the cannula  angle to  improve clot  engagement.  
The sheath  is a stainless -steel  wire  mid-wall reinforced  sheath  appropriate  stiffness  and flexibility so 
that it can be manipulated through the vasculature utilizing standard percutaneous  insertion 
techniques without kinking, collapse and deformation that may compromise t he lumen  and inhibit 
compatibility with  the catheter.  
The sheath  is provided  in a straight  configuration  with  a working  length  of 33.5  inches  and a 
nominal  diameter of  22F.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
20 
CONFIDENTIAL   
  
5.2.4 OBTURATOR  DESCRIPTION  
The obturator is used to support the sheath during insertion and re -positioning. The obturator is  
assembled from a Pebax female luer adaptor with a radiopaque (barium sulfate) doped Pebax  
shaft/Everglide  extrusion  that creates  a low friction  sliding  surface  during  placement.  The 
obturator is provided in a straight configuration with tapered tip at a length of 38.7 inches and a  
diameter  of 17F.  
 
5.2.5 ASPIRATOR  HANDLE  DESCRIPTION  
The Aspirator Handle is a syringe -like aspiration handle intended to be used with the aspiration  
cannula described above.  The aspirator handle utilizes a dual check valve to control flow; the  
upper  port allows  inflow,  while  the lower  port  enables  outflow  directed  to the waste  bag.  
 
 
5.2.6 WASTE  BAG DESCRIPTION  
The waste bag for the AlphaVac MMA F1885 PE is 250mL and intended to capture and contain the  
material  aspirated  during  a procedure  for disposal.  Each  AlphaVac  MMA  F1885 PE is packaged  with  
four  waste bags.  
 
 
5.3 MECHANISM  OF ACTION  FOR THE ALPHA VAC MMA  F1885 PE 
The utilization  of AlphaVac  MMA  F1885 PE allows  for avoidance  of complex,  high - risk surgical  
procedure  by providing  a percutaneous  treatment  option  for endo -mechanical  removal  of 
emboli/thrombus.  
Prior to the AlphaVac MMA F1885 PE procedure, the patient is prepared and  draped  in a typical  
sterile  manner  for percutaneous/surgical  vascular  procedures.  Using  percutaneous vascular 
access techniques (i.e., Seldinger techniques) and standard off -the-shelf  guidewires, and 
introducer sh eaths an appropriate venous blood vessel is accessed, by either  internal  jugular  or 
one of the common  femoral  veins.  
Once assess is gained, a guidewire is advanced into the vasculature and positioned at or just  
beyond the desired cannula tip location. The obturator and sheath are then placed over the  
guidewire  and advanced  under  fluoroscopy  into the desired  position  within  the vasculature.  Once  
at the target location  the obturator  and guidewire  are removed.  
The cannula is attached to the aspiration handle and waste bag, the system primed, and advanced  
though the sheath. As the cannula is advanced out of the sheath at the target  location the nitinol 
basket automatically expands into a funnel shape. The self -expanding nitinol  basket reinforc ed 
funnel aids in guidance and removal of undesirable intravascular material (i.e.  thrombus  or 
emboli).  
Once thromboemboli is engaged, the aspiration handle is then pulled back  creating suction and 
pulling the material into the cannula, removing it from th e vasculature. The     aspirated  material  is 
captured  and contained  within  the waste  bag for  disposal.  At the end of the procedure  the entire  
AlphaVac  MMA  F1885 PE System  is removed  from  the patient.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
21 
CONFIDENTIAL   
  
 
6 CLINICAL  STUDY  PURPOSE  AND  ENDPOINT  
6.1 OBJECTIVE  
The objective of this clinical study is to determine the safety and effectiveness of mechanical  
aspiration thrombectomy using the AlphaVac Multipurpose Mechanical Aspiration (MMA)  
F1885 PE in a prospective trial of patients with acute int ermediate -risk pulmonary  embolism  
(PE).  
 
6.2 PRIMARY  SAFETY  AND  EFFICACY  
Table  2. Primary  Endpoints  
 
 Outcome  
Primary  Efficacy:  Reduction  in the RV/LV  ratio  at 48 hours  post -procedure  assessed  
by CTA.  The primary  efficacy  analysis  will be the difference  
between  the baseline  and the 48-hour  RV/LV  diameter  ratio.  All 
CTA data will be read centrally by the core lab.  
Primary  Safety:  Rate  of major  adverse  events  post -procedure  within 48 hours 
after the index procedure. MAEs include : 
• Device -related  death   
• Major  bleeding   
• Device -related  SAEs,  which  includes:  o Clinical  
deterioration  
o Pulmonary  vascular  injury  
o Cardiac  injury  
Some examples of m ajor bleeding,  clinical  deterioration,  
pulmonary  vascular  injury,  and cardiac injury are defined in the 
study definitions of  Appendix  I. 
 
6.3 SECONDARY  ENDPOINTS  
Table  3. Secondary  Endpoints  
 
 Outcome  
Secondary  Efficacy:  • Length  of stay in ICU/Hospital  setting  within  30 days  
• Use of thrombolytics  within  48 hours  
• Change in Modified Miller Index at 48 hours post -
procedure assessed by CTA  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
22 
CONFIDENTIAL   
 Secondary  Safety:  
 • Device -related  death  within  48 hours  
• Major  bleeding  within  48 hours  
• Clinical  deterioration  within  48 hours  
• Pulmonary  vascular  injury  within  48 hours  
• Cardiac  injury  within  48 hours  
• Any-cause  mortality  within  30 days  
• Device -related  SAEs  within  30 days  
• Symptomatic  PE recurrence  within  30 days  
 
Refer  to Appendix  I for definitions.  
 
6.4 EXPLORATORY  ENDPOINT  
 
This study will collect baseline data to identify unmet social related needs such as housing 
instability, violence, financial strain, etc. Exploratory analysis may be conducted to evaluate 
healthcare disparities, unmet healthcare needs with study enrollments and outcomes.  
The accountable health communities (AHC) health - related social needs screening tool (HRSN)1 
will be completed by all enrolled patients at their baseline visit.  
 
 
7 STUDY DESIGN  
7.1 STUDY  DESCRIPTION  
This is a prospective, multicenter, single arm study. This study will include up to 122 patients at up 
to  30 centers  in the United States. Each  subject will  be in  the trial for approximately  30 days.  
 
7.2 STUDY  POPULATION  
This study will collect data on sympt omatic patients with acute intermediate -risk PE. The enrolled  
patients will be treated with aspiration thrombectomy by the AlphaVac Multipurpose Mechanical  
Aspiration  (MMA)  F1885 PE. 
 
7.2.1 INCLUSION  CRITERIA  
All the following  criteria  must  be met in order  to be enrolled  and continue  participation  in the 
study:  
1. Provision  of signed  and dated  informed  consent  form.  
2. Subject is  18 years  of age and older.  
3. Subject presents clinical signs and symptoms consistent with acute intermediate -risk 
pulmonary embolism  for less than  or equal  to 14  days.  
4. Subject  has a diagnosis  of pulmonary  embolism  detected  from  computed  tomography  
angiography  (CTA).  
5. Subject  has a RV/LV  ratio  of 0.9 or higher.  
6. Subject  has a systolic  blood  pressure  (SBP)  of 90mmHg  or higher  
7. Subject  has a heart  rate of 130 beats  per minute  (BPM)  or less prior  to the procedure.  
8. Subject  is deemed  medically  eligible  for interventional  procedure(s)  per institutional  
guidelines  and/or  clinical  judgement.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
23 
CONFIDENTIAL   
  
7.2.2 EXCLUSION  CRITERIA  
A potential  subject  will be excluded  from  the study  if he/she  meets  any of the following  exclusion  
criteria:  
 
Exclusion  Criteria  
A potential  subject  will be excluded  from  the study  if he/she  meets  any of the following  exclusion  
criteria:  
1. Subjects  who  are or may  be pregnant  as determined  by a positive  pregnancy  test or who  
are breastfeeding.  
2. Subjects  who  have  any contraindication  to systemic  or therapeutic  doses  of heparin  or 
anticoagulants.  
3. Subjects  who  have  used  thrombolytics  (tPA)  in the past  30 days  of baseline  CTA. 
4. Subjects  who  have  pulmonary  hypertension  with  peak  pulmonary  artery  pressure  
(PAP)  > 70  mmHg.  
5. FiO2  requirement  >40%  or >6 LPM to  keep  oxygen  saturations  >90%  
6. Subjects  with  hematocrit  <28%  within  6 hours  of index  procedure.  
7. Subjects  with  platelets  count  < 100,000/µL.  
8. Subjects  with  serum  creatinine  >1.8  mg/dL.  
9. Subjects  with  International  Normalized  Ratio  (INR)  > 3. 
10. Subjects  who  have  undergone  a major  trauma  within  the past  14 days  of the index  
procedure  and have Injury  Severity  Score (ISS)  > 15.  
11. Subjects  with  the presence  of cancer  requiring  active  chemotherapy.  
12. Subjects  with  known  bleeding  diathesis  or coagulation  disorder.  
13. Subjects who have had a cardiovascular or pulmonary surgery within the past 7 days of  
index  procedure.  
14. Subjects  with  a histo ry of severe  or chronic pulmonary  hypertension , uncompensated heart failure, 
chest irradiation, underlying lung disease that is oxygen dependent, Heparin - induced 
thrombocytopenia  (HIT) and/or chronic left heart disease with left ventricular ejection fract ion ≤ 
30%.  
15. Subjects  with  known  anaphylactic  reaction  to radiographic  contrast  agents  that cannot  
be pretreated.  
16. Subject  requires  Vasopressor  after  fluids  to keep  pressure ≥  90mmHg.  
17. Subjects  with  left bundle  branch  block.  
18. Subjects  who  have  intracardiac lead  in the right  ventricle  or atrium.  
19. Evidence  such  as imaging  or other  that suggest  the subject  is not appropriate  for this 
procedure.  
20. Subjects  that have  life expectancy  < 90 days.  
21. Subjects  dependent  on extracorporeal  life support  such  as extracorporeal  membrane  
oxygenation  (ECMO).  
22. Participation  in another  investigational  study.  
7.3 STUDY  ENROLLMENT  
Patients presenting with signs and symptoms of acute intermediate risk PE will be screened for  
possible  enrollment as  a patient into  the trial base d on Inclusion/Exclusion  Criteria.  
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
24 
CONFIDENTIAL   
 7.3.1 ENROLLMENT  PROCEDURE  
Consecutive  patients  presenting  with  acute  intermediate -risk PE will be screened  for this trial.  
Those who do not meet the study’s Inclusion/Exclusion Criteria will not be enrolled with the  
reason  recorded.  
A patient  is considered  enrolled  once  the patient  informed  consent  form  and HIPAA  Authorization  
are signed  by the patient,  and in whom  the AlphaVac  Multipurpose  Mechanical  Aspiration  (MMA)  
F1885 PE has been  introduced into  their  body.  
 
Any patient  enrolled  into the trial,  but in whom  the AlphaVac  Multipurpose  Mechanical  
Aspiration (MMA) F1885 PE is not able to access a pulmonary embolus is considered an as  treated  
patient  and will be monitored  per protocol  until  the end of required  follow -up period  of 30   days. 
Any patient that experiences an adverse event after venous puncture but in whom the  Cannula  
is not inserted will be  monitored through  discharge  for safety.  
 
Refer  to Warnings,  Precautions,  and Potential  Adverse  Events  in the Instructions  for Use prior  to 
use. 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
25 
CONFIDENTIAL   
  
 
8 STUDY  PROCEDURES  
 
8.1 STUDY  PROCEDURES  
All data elements for all subjects will be collected using electronic case report forms (eCRFs). Source  
data  originally  captured  in electronic  format  may  be used  to populate  eCRF  data  fields  where  possible  
to reduce unnecessary duplication of data and to reduce the possibility of transcription errors.  Data  
will be entered into the eCRFs at screening, baseline/index procedure, at 48 - Hours, disch arge, and  
at 30 - days post procedure or until death, and in accordance with the adverse event procedures  
described  below.  Sites  will be requested  to adhere  to guidelines  for the treatment  and monitoring  of 
these  subjects.  Planned  Source  Data  Verification  (SDV)  will be 100%  for all endpoint -related  data.  
 
8.2 STUDY  VISITS  
 
Table  4: Study  Visits  
 
Visit  Data  Collection  
Screening:  • Medical  History  
• Demographics  
• Vital  signs  
• Hematocrit/FiO 2/Creatinine/Platelets/INR/Troponin  
• CTA (RV:LV  Ratio)  
• Concomitant  Medications  
• Pregnancy  Test  
• Hospital  admission  date  
Baseline/Index  Procedure  (Day  1): • AHC -HRSN Screening Tool1 
• Date  of procedure  
• Vital  signs  (0- 48 Hours  before  the procedure)  
• Venous  puncture  for AlphaVac  MMA  F1885 PE Procedure  
• Pre procedure  Pulmonary  Artery  Pressure  
• Post  procedure  Pulmonary Artery  Pressure  
• Concomitant  Medications  
• Device  Used  
• Time  of Device  Insertion  
• Bleeding:  Major  and Minor  
• Adverse  Events  
48 Hour  Post – Procedure  (±6 hr.): • Vital  signs  
• Hematocrit/FiO 2/Creatinine/Platelets/INR/Troponin  
• CTA (RV:LV  Ratio)  
• Concomitant  Medications  
• Bleeding:  Major  and Minor  
• Adverse  Events  
Discharge  • Vital  signs  
• Concomitant  Medications  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
26 
CONFIDENTIAL   
 • Bleeding:  Major  and Minor  
• Adverse  Events  
• Hospital  Discharge  Date  
30 Day Follow -Up (± 7 days)  
(Virtual or In -Person)  • Vital  signs  (if the patient completes the 30 -day follow up visit in 
person or if deemed necessary after the virtual visit ) 
• Concomitant  Medications  
• Symptomatic PE  Recurrence  
• Adverse  Events  
• The “Study Completion Form” CRF will be filled in at the end of  the 
study (even if the patient is lost to follow -up before  the 30-day visit, 
withdrew  consent,  or expired).  
8.3 ADJUNCTIVE  TREATMENTS  
There  may  be circumstances  for the need  to use other  treatments  to aid the AlphaVac  Multipurpose  
Mechanical  Aspiration  (MMA)  F1885 PE in recanalizing the  targeted  vessel.  
 
Adjunctive treatments will be considered as a protocol deviation unless used to treat clinical  
deterioration.  These adjunctive  treatments  will be  recorded  on the CRF.  
 
9 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  
9.1 PARTICIPANT  WITHDRAWAL  
Each  subject  has the right  to withdraw  from  the study  at any time.  In addition,  the investigator  may  
discontinue a participant from the study at any time if the investigator considers it necessary for  
any reason  including:  
• Ineligibility  (either  arising  during  the study  or retrospectively  having  been  overlooked  at 
screening)  
• Consent  withdrawn  
• Lost to follo w-up 
 
9.2 TERMINATION  OF PATIENT  PARTICIPATION  
All patients  have  the right  to terminate  their  participation  at any point  during  the study.  In addition,  
Principal  Investigators  also have  the ability  to terminate  patient  participation  in the study.  Reasons  
for termination  include  completion  of study,  patient  withdrawal,  physician  directed  patient  
withdrawal, lost -to-follow -up, and death. A description of the reason for their termination will be  
documented  in the patient’s  medical  file and in the appropriate  study  Case  Report Forms  (CRF).  
 
9.3 SCREEN  FAILURE  
The reason  for screen  failure  will be captured  in the screening/enrollment  section  of the database.  
 
• Subjects  who  were  evaluated  and do not meet  the Entry  Criteria  
• Subjects  who  meet the  Entry  Criteria  but decline  to participate  in the trial.  
• Subjects  who  meet  the Entry  Criteria,  but do  not have  any component  of the study  device  
(AlphaVac MMA F1885 PE, described in Section 5.2) introduced into the  body  
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
27 
CONFIDENTIAL   
 9.4 LOST TO FOLLOW -UP 
 
• A subject will be considered lost to follow -up if he or she fails to meet any of the following:  
return  to the treating  or care  managing  physician’s  office  for scheduled  routine  follow -up visits,  
fail to be available remotely (e.g. , by phone) to report safety (AEs and relevant medications)  
information,  or) and is unable to  be contacted by  the study site staff.  
• The site will attempt to contact the patient and reschedule the  missed visit and counsel the  
patient on his/her obligation of maintaining the assigned visit schedule and ascertain if the  
participant wishes  to and/or  should  continue  in the study.  
• Before  a subject  is deemed  lost to follow -up, the investigator  or designee  will make  every  effort  
to regain contact with the subject (e.g., 3 telephone calls to subject or next of kin, a certified  
letter to the participant’s last known mailing address, email to subject or next of kin, inquiries  
to other k nown healthcare providers). These contact attempts should be documented in the  
subject’s  medical  record  or study file.  
• Should the subject continue to be unreachable and the reason for failure to respond has not  
been determined to be health related, he or s he will be considered to have withdrawn from  
the study with  a primary reason  of lost to follow -up. 
 
10 STUDY  ASSESSMENTS  AND ADVERSE EVENT  REPORTING  
Assessment  and reporting  of safety  events  will follow  all national  and local  laws  and requirements  for the 
conduct of  clinical  studies.  
 
10.1 ADVERSE  EVENTS  
For the purpose  of this clinical investigation  plan, an  adverse event (AE) is any untoward  medical  
occurrence,  unintended  disease  or injury  or any untoward  clinical  signs  in subjects  whether  or not related  
to the Investigational Product and includes events related to the procedures involved (any procedure in  
the clinical  investigation  plan).  Safety  events  will refer  to all peri  procedural  MAEs  (PPMAEs),  serious  AEs 
(SAEs),  Major  AEs (MAEs),  adverse  device  effects  (ADEs)  (including  serious  adverse  device  effects  
[SADEs]),  and (severe)  unanticipated  adverse  device effects  (UADEs/SUADEs).  
 
For the purposes of this study, any untoward medical occurrence that occurs in a subject is considered  
an AE. 
 
Any medical conditions, problems, signs, symptoms, and findings that are occurring at the time of  
screening are to be reported as pre -existing conditions. Such conditions should be documented and  
reported  on the Medical  History  eCRF  as pre-existing  conditions.  If a pre-existing  condition  worsens  
during follow -up (frequency increases and/or severity grade increases), it should be documented as an  
AE per the definitions  mentioned  above.  
 
At each evaluation from the time of enrollment, the investigator or designee will determine whether an  
AE as described  has occurred.  The AE description,  date  of onset,  seriousness,  severity,  duration,  
treatment,  outcome,  and relationship  to the underlying  disease,  procedure  and investigational  device  will 
be recorded on the AE CRF. Adverse events will be assessed by a physician and monitored until they are  
adequately  resolved, stabilized,  or the subject has  reached  study  completion.  
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
28 
CONFIDENTIAL   
 All SAEs (including SADEs) and suspected UADEs  will be documented for all  patients, regardless of  
treatment, through the end of the period of evaluation for SAEs, or until the subject is withdrawn from  
study  participation  (for any reason).  
 
The term "severity" refers to the intensity of a specific event (mild, moderate, or severe). An event can  
be severe but of relatively minor medical significance (such as severe erythema), thus not serious.  
Seriousness  (as opposed  to severity)  serves  as a guide  for defining  regulatory  reporting  obligations.  
 
The Adverse  Event  Severity  Scale,  found  in the table  below,  provides  the definitions  which  will be used  to 
determine  the severity of  each  AE: 
 
Table  5. Adverse  Event  Severity  Scale:  
 
Grade  Severity  Description  
1 Mild  Awareness  of a sign or symptom  that does  not interfere  with  the patient’s  
usual  activity;  or is transient  (<48  hours)  and 
resolves  without  medical  intervention/therapy  required.  
2 Moderate  Interferes  with  the patient’s  usual  activity  (some  assistance  maybe 
needed ) and/or  no or minimal   medical  
intervention/therapy  is required.  
3 Severe  Symptoms causing severe discomfort with marked limitation  in activity,  
some  assistance  usually  is required;  medical  intervention/therapy  is 
required,  and hospitalization  is possible.  
4 Life-
threatening  Extreme limitation in activity, significant assistance required;  significant  
medical  intervention/therapy  required,  hospitalization  or hospice care  
possible  
5 Death  Death related to AE  
 
For each  corresponding  AE identified  in the study,  an authorized  investigator  must  assess  the relationship  
of the AE to the study devices. Clinical investigators must determine whether there is a reasonable  
possibility that the study devices caused or contributed to an AE. The relationship assessmen t, based on  
clinical  judgment, often relies on  the following:  
 
• A temporal  relationship  between  the event  and application  of the study  devices  
• A plausible  biological  mechanism  for the device  to cause  the AE, 
• Another  possible  etiology  for the AE 
• Previous  reports  of similar  AEs associated  with  the device  or other  devices  in the same  class,  and 
• Recurrence  of the AE after  re-application  of the same  device  or conversion  to another  device,  if applicable
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
29 
CONFIDENTIAL   
  
 
10.1.1  DEFINITION  OF SERIOUS  ADVERSE EVENT  (SAE)  
Serious  AEs are a subset  of AEs.  An SAE is  one that:  
1. Results  in death  
2. Results  in life-threatening  illness  or injury  
3. Results  in a permanent impairment  of a body  structure  or function  
4. Requires  inpatient  hospitalization  or prolongation  of an existing  hospitalization  
5. Results  in a medical  or surgical  intervention  in order  to prevent  a permanent  impairment  to a 
body  structure or  function, or  
6. Results  in fetal  distress,  fetal  death,  or a congenital  abnormality  or birth  defect  
7. Important medical event  
 
A planned inpatient hospitalization, without a serious deterioration in health, is not considered to be  
a serious  adverse  event.  Reports  relating  to the subject’s  subsequent  medical  course  must  be 
submitted  to the sponsor  or sponsor’s  designee  and the reviewing  IRB (if required)  until  the event  has 
subsided  or, in the case  of permanent  impairment,  until  the event  has stabilized  and the overall  clinical  
outcome has been ascertained. As for prolongation of hospitalization for the index procedure, the  
protocol considered an SAE of prolonged hospitalization if a subject is discharged from the facility  
more than  24 hours  than  the extended  hospitalization  (for the procedure)  per hospital  practice.  
 
When  an investigator  determines  that an event  does  meet  the definition  for a SAE (as defined  above),  
the investigator or Research Coordinator must report the event within 10 days of becoming aware of  
the event  to the sponsor  or sponsor’s  designee  and reporting  at the number  provided  by the Contract  
Research  Organization  (CRO).  Additionally,  reports  must  be provided  to the reviewing  IRB per national  
and local  requirements.  All SAEs,  including  serious  ADEs  (SADEs)  will be recorded  as per investigator’s  
reporting in  the CRF.  
 
10.2 ADVERSE  DEVICE  EFFECTS  
Adverse device effects (ADEs) are a subset of adverse events. The ADEs are only those AEs caused by or  
related to Thrombectomy procedure performed by the AlphaVac Multipurpose Mechanical Aspiration  
(MMA) F1885 PE (possibly, probably and definitely related), including any AE resulting,  the lasing, or any 
malfunction of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE, including  any event 
that is a result of  a use error  or intentional  misuse.  
 
With any procedure or treatment, there are known possible risks and complications. With the AlphaVac  
Multipurpose Mechanical Aspiration (MMA) F1885 PE, all risks known for the proposed  indication can be 
found in Section 10.11.  A list of precautions and warning concerning use of the device  is found  in the 
device’s IFU.  
 
10.3 UNANTICIPATED  ADVERSE  DEVICE  EFFECTS  (UADE)  
Investigators  are required  to submit  a report  of any suspected  UADE  occurring  during  an investigation  to 
the sponsor  or sponsor’s  designee  as soon  as possible,  but not later  than  10 working  days  after  the 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
30 
CONFIDENTIAL   
  
investigator first learns of the effect. Additionally, reports must be provided to the reviewing IRB per  
national  and local  requirements.  
 
When an investigator suspects an event meets the definition for a UADE, then the event, date of onset,  
seriousness, severity, duration, treatment, outcome and relationship to investigational device will be  
recorded  on the Adverse Event CRF.  
 
The sponsor or sponsor’s designee must then conduct an evaluation of the suspected UADE and report  
the results  of the findings  to the FDA and to all reviewing IRBs  (if required)  and participating  investigators  
within 10 working days after the sponsor or sponsor’s designee first receives notice of the effect.  
Thereafter, the sponsor or sponsor’s designee shall submit such additional reports concerning the effect  
as FDA requests.  
 
This information  must  be submitted  via the CRF.  Information  includ es: 
 
• Clinical  investigation  plan  number/identifier  
• Subject  identifying  information  
• Initial  diagnosis  (nature  of suspected  UADE)  and results  of any diagnostic  tests  supporting  
diagnosis  
• Date(s)  of use of investigational  device  
• Date  of event, treatment,  and outcome  (current  clinical  status)  
• Statement  as to why event was  unanticipated  
• Relationship  to the investigational  device.  
• Investigator’s  signature  and date 
• Other  pertinent  information  as required  by the sponsor  or sponsor’s  designee.  
• Reports  relating  to the subject’s  subsequent  medical  course  must  be submitted  to the sponsor  or 
sponsor’s  designee  and the reviewing  IRB (if required)  until  the event  has subsided  or, in the case  
of permanent impairment, until the event has stabilized, and the overall clinical outcome has  
been  ascertained.  
 
10.4 RELATIONSHIP  TO STUDY DEVICE : 
For each AE identified in the study, an authorized investigator must assess the relationship of the  
AE to the study devices. Clinical investigators and CEC review and adjudication must determine  
whether  there  is a reasonable  possibility  that the study  devices  caused  or contributed  to an AE. The 
relationship  assessment,  based on  clinical  judgment, often  relies  on the following:  
• A temporal  relationship  between  the event  and application  of the study  devices  
• A plausible  biological  mechanism  for the device  to cause  the AE 
• Another  possible  etiology  for the AE 
• Previous reports of similar AEs associated with the device or other devices in the  
same  class,  and 
• Recurrence  of the AE after  re-application of the same  device  or conversion  to 
another  device, if  applicable  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
31 
CONFIDENTIAL   
  
The following  definitions  for Adverse  Event  Relationships,  in the table  below,  will be used  to 
determine  the relationship  of each  event  to the study  device  or study  participation:  
Table  6: Adverse  Event  Relationships  
 
Not related  The cause of the AE is known and is not related to any aspect  
of study  participation  including  the underlying  condition  or 
concurrent  illness  or effect of  another  device  or drug.  
Possibly  related  There  is a reasonable  possibility  that the event  may  have  been  caused  by 
study  participation.  The AE has a timely  relationship  to the study  
procedure(s);  however,  it follows  no known  pattern  of response , and 
an alternative  cause  seems  more  likely  or there  is significant  uncertainty.  
Probably  related  It is probable  that the event  was caused  by study  participation.  The AE 
has a timely  relationship  to the study  procedure(s)  and follows  a 
known  pattern  of response , but a potential  alternative  cause  may  be 
present.  
Definitely  
related  The event  was definitely  related  to study  participation.  A related  event  
has a strong  temporal  relationship,  and an alternative  cause  is unlikely.  
 
 
10.5 DEATH  NOTICE  
When a site becomes aware of a subject’s death, it should be reported to the sponsor or sponsor’s  
designee  within  10 days,  by way of completion  of the appropriate  CRF,  and to the FDA and the reviewing  
IRB per local  requirements.  
 
The materials  to be submitted  for a death  are due within  10 days  of becoming  aware  of the death  and 
consist  of emailing or faxing  the following  reports  to the sponsor  or sponsor’s  designee:  
• Death narrative: A short description by the treating physician regarding the circumstances of  
death  and an assessment  as to whether  the death  is related  to study  interventions.  
• A copy  of the patient’s  death  certificate  (If available).  
• For reported deaths, the clinical investigator or designee should supply the sponsor or sponsor’s  
designee and IRB with any additional requested information if available (e.g., hospital records  
and autopsy reports).  
 
If the above  reports  are not available  to the site within  10 working  days,  the site must  notify  the sponsor  
or sponsor’s  designee  when  they  will be available.  
 
10.6 DEVICE  COMPLAINT  AND  MALFUNCTION  
Device complaints include any deficiencies regarding the investigational device, IFU, and other product  
related  documentatio n. 
 
Device  complaints  may  result  in a safety  event  and if so should  be reported  and adjudicated  as an adverse  
device effect (ADE or UADE). Complaints and malfunctions not adversely affecting the safety of the  
patient should be reported to the sponsor or sponsor’s designee and properly collected in the Device  
Malfunction CRF. Where necessary, the sponsor may require that the device be returned for additional  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
32 
CONFIDENTIAL   
 evaluation.  All device failures  will be reported  at the  conclusion  of the clinical  study.  
 
For any event involving suspicion of a device malfunction, the sponsor may request that the clinical  
investigator return the device (when possible) for further evaluation. Device malfunctions or failures are  
not to be reported as AEs. Howe ver, if there is an AE that results from a device failure or malfunction,  
that specific  event  would  be recorded  as described in  Section  10.1.  
 
10.7 MEDICAL  MONITORING  
It is the responsibility of the principal investigator to oversee the safety of the study at his/her site. If for  
example, the patient experiences clinical symptoms relating to a suspected PE recurrence in the treated  
vessel following the index procedure, the PE recurrence should be managed per institutional guidelines  
or at investigator discretio n. This safety monitoring will include careful assessment by the principal  
investigator  and appropriate reporting of  all safety  events  as noted  above.  
 
The principal investigator or qualified delegate must review and verify the completed AE form for  
accura cy and completeness. This physician also makes the site’s final assessment of the relationship  
between  the device/procedure  and the AE. When  possible,  the principal  investigator  should  designate  at 
least one other study physician who can perform the assessment of AE/SAE/SADE/UADE to provide  
uninterrupted  coverage of  monitoring  of AEs which  require  expedited reporting.  
 
Medical  monitoring will  also include  a regular  assessment  of the number  and type  of safety  events.  
 
10.8 HANDLING  AND REPORTING  SAFETY EVENTS  
Subjects will be carefully monitored during the study for possible safety events. All AEs will be  
collected  actively  and deliberately  at predefined  study  intervals  and shall  be reported  and 
documented  on the appropriate  eCRF (Adverse  Events).  All observations  and clinical  findings,  
including  the nature,  seriousness,  severity,  and relationship  to the device  and/or  pulmonary  
embolism  will be assessed  by the investigator  and provided  on the CRF.  This documentation  will also 
include a detailed description of the event, treatments rendered in response to the event and  
outcomes  of the treatment.  
Additionally, an independent Data Monitoring Committee (DMC) will be established to monitor  
the safety  and conduct  of the clinical  study,  including  adherence  to the clinical  investigation  plan.  
The DMC will follow the statistical analysis plan (SAP) and the clinical investigation plan specific  
DMC  Charter.  
The investigator will report any and all safety events to the sponsor as soon as possible after  
becoming aware of the event. Reporting may occur by telephone at the number provided by the  
Sponsor . 
 
10.9 DATA  MONITORING  COMMITTEE (DMC)  
A DMC  will be established  to review  cumulative  study  data  to evaluate  safety  (interim  and 
cumulative  data  for AEs),  study  conduct,  and scientific  validity  and integrity  of the trial.  The DMC  will 
consist  of at least  3 independent  subject  matter  experts  who  will be voting  members  and a 
Statistician (voting or non -voting). The three voting members will be physicians not associated with  
the study in any capacity or have any affiliations with the study sponsor or sponsor’s designee, and  
without any direct business associations with the principal investigator of the trial. The physicians  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
33 
CONFIDENTIAL   
 may  be selected  from  different  disciplines  but with  an understanding  of the study  population  and 
procedures. None of the members will have direct involvement in the conduct of the study or have  
any conflict of interests. The initial DMC meeting will develop the DMC Charter which will contain  
operational  details  including  schedule  for meetings,  triggers  set for data  review  or analyses,  
definition  of a quorum,  and stopping  rules  for safety.  
The conduct of the DMC will be guided by the FDA guidance on the “Establishment and Operation  
of Clinical Trial Data Monitoring Committees for Clinical Trial Sponsors.” The decision to implement  
the recommendations of the DMC will be made by the Sponsor, following consultation with the  
coordinating Investigator(s).  
 
10.10  CLINICAL  ENDPOINT  ADJUDICATION  COMMITTEE  (CEC) 
An independent CEC will be established for the purpose of reviewing clinical endpoints including  
safety and /or effectiveness data. The CEC will consist of medical doctors who will not have direct 
involvement of the conduct of the study . The CEC will meet regularly to review and adjudicate 
appropriate adverse events for  causality  and attribution.  
 
 
10.11  RISK BENEFIT  ANALYSIS  
The clinical  investigation  plan  has been  designed  to ensure  that a subject’s  risks  will be minimized.  
Specific processes include training of physicians on appropriate devise use, stopping rules, and  
ongoing DMC  oversight.  This device, as do all embolectomy systems and devices, has possible 
side effects, which include, but are not limited to infections, blood loss, thrombus formation, 
embolic events, vessel, ventricular or valvular damage and complications of percutaneous or  
surgical insertion techniques. These may occur if the Directions for Use are not followed.  
Possible  complications  include  those  normally  associated  with  large  bore  surgical  and/or  
percutaneous vessel cathe terization/cannulation, anticoagulation, and appl ication of 
intravascular  introducer  systems  which  include  but are not limited to:  
 
• Air Embolism  
• Arrhythmia  
• Arteriovenous Fistula  
• Blood Loss/Blood Trauma  
• Bradycardia  
• Tachycardia  
• General Discomfort, Tenderness, or Pain  
• Hemorrhage /Bleeding  
• Infection (Local or Systemic)  
• Pleural Effusion  
• Pericardial Effusion  
• Pulmonary Embolism  
• Pulmonary Infarction  
• Injury  to Blood  Vessel  
• Device Fracture  with Distal Embolization  
• Distal Embolization of Thrombus  
• Hematoma  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
34 
CONFIDENTIAL   
 • Access Site  Injury  
• Vascular Thrombosis  
• Valve Injury  
• Perforation   
• Vessel Spasm  
• Hemoptysis  
• Death  
• Cardiac arrest  
• Hemothorax  
• Pulmonary Artery Injury/Wire Perforation  
 
Benefits  may  include  improvement  in the subject’s  disease  state.  
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
35 
CONFIDENTIAL   
  
11 STATISTICAL  CONSIDERATIONS  
11.1 GENERAL  CONSIDERATIONS  
Standard statistical methods will be employed to analyze all data. All data collected in this study will be  
documented using summary tables and patient data listings. Continuous variables will be summarized  
using descriptive statistics, including counts, mean, medi an, standard deviation (SD), minimum and  
maximum. Where appropriate, 95% two -sided confidence intervals for the means will be presented.  
Categorical  variables  will be summarized  by frequencies  and percentages.  Unless  explicitly  stated  
otherwise,  percentage s will utilize  a denominator  corresponding  to the number  of unique  patients.  
 
 
11.2 DETERMINATION  OF SAMPLE  SIZE 
This study  is designed  to assess  the efficacy  of the AlphaVac  Multipurpose  Mechanical  Aspiration  (MMA)  
F1885 PE with  respect  to the primary  efficacy  endpoint  (reduction  in RV/LV  Ratio  between   baseline and 48 
hours post procedure) as well as to assess the safety of the AlphaVac MMA F1885 PE with respect to the 
primary safety endpoint (rate of any MAE within 48 hours of the  procedure).  
The safe ty performance goal is that less than 25% of study subjects experience an MAE (the primary safety 
endpoint). This is based on the upper limit of the 95% confidence interval for the average composite MAE 
rate (16.3%) observed across 7 RCTs in which acute PE  was treated with thrombolysis versus an 
anticoagulant control.6,8,10,11,12,13,14 For this study, the hypothesized composite MAE rate is expected to be 
approximately 15%. To detect a difference between an expected MAE rate of 15% and the performance 
goal o f 25% with 80% power, the necessary sample size was calculated to be 103 (with a one -sided p -
value = 0.05). A sample size of 103 patients was selected as a conservative sample size to assess safety 
with adequate statistical power. To account for attrition rate of 15%, 122 subjects will be enrolled.  
 
Table  7: Sample  Size Determination - Safety  
 
Endpoint  Primary  
Analysis  
Population  Assumed Performance of  
Manual Mechanical  
Aspiration Catheter  Performance  
Goal  Power  Sample  
Size 
Rate  of any 
MAE  As treated  15%  25%  80%  103 
 
The efficacy performance goal of 0.12mm reduction in the RV/LV Ratio from baseline was calculated using 
4 randomized controlled trials that discuss the treatment of acute PE with anticoagulants, which is 
standard of care. The mean decrease in RV/LV ratio across the 4 trials was 0.12mm.6,7,8,9 A standard 
deviation of 0.25mm was based on the standard deviation of the RV/LV ratio observed in the FLARE trial.10 
 
Table  8: Sample  Size Determination - Efficacy  
 
Endpoint  Primary  
Analysis  
Population  Assumed 
Performance of  
Manual Mechanical  
Aspiration Catheter  Assumed 
Standard 
Deviation  Performance  
Goal  Power  Sample  
Size 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
36 
CONFIDENTIAL   
 Reduction in 
RV/LV  Ratio  Modified as 
treated  0.20  0.25  0.12  80%  62 
 
 
 
 The SAS code and resulting output for each sample size calculation is included below:  
 
 proc  power ; 
pairedmeans  sides = U 
test = diff  
nulldiff = 0.12  
meandiff  = 0.20  
power  = 0.8 
corr = 0.5 
npairs  = . 
std = 0.25 ; 
run; 
 
 
 
 proc  power ; 
     onesamplefreq  test = z method = normal  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
37 
CONFIDENTIAL   
        sides  = 1 
        alpha  = 0.05  
  nullproportion  = 0.25  
       proportion  = 0.15  
       ntotal  = . 
       power  = .80; 
run; 
 
 
 
11.3 ANALYSIS  COHORT S 
 
11.3.1  AS TREATED POPULATION  
The As Treated population includes all subjects who me et the inclusion/exclusion criteria and  in who m 
the F1885 cannula is placed within the jugular or one of the common femoral veins . This population will 
serve as the primary analysis cohort  for all safety endpoints and  as a supportive  analysis  cohort for all 
efficacy  endpoints.  
 
11.3.2  MODIFIED  AS TREATED POPULATION  
The Modified As Treated  population  includes  all subjects  in the As Treated population who  did not receive  
thrombolytics  during  the index  procedure.  This population  will        be used as  the primary analysis  cohort  for 
all efficacy endpoints.  
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
38 
CONFIDENTIAL   
 11.3.3  PER PROTOCOL POPULATION  
 
Per Protocol population: This population includes all subjects in the Modified As Treated population who had no major protoco l 
deviations.  This population will serve as a support ive analysis cohort for all efficacy endpoints.  
11.4 STUDY  ENDPOINT ANALYSIS  
11.4.1  PRIMARY  EFFICACY  ENDPOINT  ANALYSIS  
The primary  efficacy  analysis  will be the reduction  in the RV/LV  Ratio  between  Baseline  and 48 hours  post  
procedure. The mean reduction in the RV/LV Ratio will be compared to a performance goal of 0.12. The  
hypothesis  for reduction  from  baseline  in RV/LV  Ratio  is as follows:  
 
H0: Rdiff < 0.12  
H1: Rdiff ≥ 0.12  
 
Where  Rdiff is the mean  reduction  in the RV/LV  Ratio  between  Baseline  and 48 hours  post  
procedure.  
The mean  reduction  in the RV/LV  Ratio  will be compared  to the performance  goal  of 0.12  using  a paired - 
samples  t-test with  a significance level  of 0.05.  
 
 
11.4.2  PRIMARY  SAFETY  ENDPOINT ANALYSIS  
The primary  safety  analysis  will be the rate of any MAE  within  the first 48 hours  after  the index  procedure.  
MAEs  include : 
o Device -related  death  
o Major  bleeding  
o Device -related SAEs which includes:  
• Clinical  Deterioration  
• Pulmonary  Vascular  Injury  
• Cardiac  Injury  
Examples of m ajor bleeding,  clinical  deterioration,  pulmonary  vascular  injury,  and cardiac  injury  are 
defined  in Appendix  I. 
 
The proportion  of subjects  who  experienced  any MAE  within  48 hours  will be compared  to a performance  
goal  of 25%.  The hypothesis  for the rate of  any MAE  is as follows:  
 
H0: MAE  > 0.25  
H1: MAE  ≤ 0.25  
 
Where  MAE  is the proportion  of subjects  who  experienced  any MAE  within  48 hours  of the 
procedure.  
The rate of any MAE within 48 hours of the procedure will be compared to the performance goal of 25%  
using a  one sample proportion  test with  a significance  level of  0.05.  
 
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
39 
CONFIDENTIAL   
 11.4.3  SECONDARY  EFFICACY  ENDPOINT  ANALYSIS  
The secondary  efficacy  endpoints  will include  the following:  
1. Length  of stay in ICU/Hospital  setting  within  30 Days  
2. Use of thrombolytic  within  48 hours  of the index  procedure  
3. Change in modified miller index between baseline and 48 hours of the index procedure  
 
Length  of stay in the ICU/Hospital  setting  within  30 days  and the change in modified miller index will be 
summarized  descriptively.  Point  estimates    will be reported. For all other secondary efficacy endpoints, 
the number  and proportion of patients who experienced each endpoint will be presented.  
 
 
11.4.4  SECONDARY  SAFETY  ENDPOINT  ANALYSIS  
1. Major  bleeding  within  48 hours  
2. Device -related  death  within  48 hours  
3. Device -related  clinical  deterioration  within  48 hours  
4. Device -related  pulmonary  vascular  injury  within  48 hours  
5. Device -related  cardiac  injury  within  48 hours  
6. Any-cause  mortality  within  30 days  
7. Device -related  Serious  Adve rse Events  within  30 days  
8. Symptomatic  recurrence  of PE at  30 days  (Recurrent  pulmonary  embolism  is defined  in the 
Study  Definitions  of Appendix  I). 
 
The number and proportion of patients who experienced each of the secondary safety endpoints will be  
presented.  
 
11.4.5  EXPLORATORY END POINT  ANALYSIS  
 
Exploratory analysis may be conducted to evaluate healthcare disparities, unmet healthcare needs with 
study enrollments and outcomes.  
 
11.4.6  SUBGROUP  ANALYSIS  
Subgroup  analyses  are exploratory  in nature  and may  include  demographic  information,  baseline  
characteristics, and other factors to be determined after the study team reviews the final analyses of  
primary  and secondary endpoints.  
 
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
40 
CONFIDENTIAL   
  
11.5 ADVERSE  EVENT  ANALYSIS  
All adverse  events  will be coded  according  to the Medical  Dictionary  for Regulatory  Activities  (MedDRA).  
The number and percent of subjects in the as treated population who experience each AE will be 
summarized  by MedDRA system organ class and preferred terms. Serious adverse events will also be 
presented in a  by-subject listing.  
 
11.6 PROTOCOL  DEVIATIONS  
Patients  with  protocol  deviations  will be summarized  in data  listings.  All enrolled  patients  will be included  
in the reporting  of protocol deviations.  Patients with major protocol deviati ons as defined in the 
Protocol Deviation Plan  will be excluded from the Per Protocol analysis.  
11.7 HANDLING  MISSING  DATA  
Missing data are defined as data that are expected to be collected but are not available for the study at  
the time of the final analysis. In this study, missing data will not be imputed nor handled with the last  
observation carried forward. In general, data will be analyzed as they are recorded with the following  
specific methods  apply to  defining  and handling  missing  data.  
• Patients  who  drop  out before  study  completion  will not be replaced  and all information  obtained  
from  them  will be included  in the analysis.  
• Missed  visits:  If a patient  missed  a visit,  information  to be collected  during  that visit is considered  
as missing  data.  Patients  with  a missing  visit will be removed  from  the analysis for that visit. For 
example, subjects without a 30 -Day follow -up visit will not be  included  in the analysis  of the 
symptomatic  PE recurrence  secondary endpoint.  
• Missing data: We expect relatively few patients to be missing the primary endpoint s due to 
withdrawal or refusal  due to the short study follow -up period.  The Electronic Data Capture (EDC) 
supports efficient data collection and management and faci litates rapid data closure. The 
frequency of missing data can be reduced by two mechanisms : the coordinators will receive a list 
of queries generated by the study monitors upon logging into the s ystem, and any data required 
during a visit is immediately ev ident through the system and can be collected before closure of 
the visit window.  Despite the screening and ongoing communication with patients regarding the 
importance of study endpoint assessment, we anticipate no more than 15 % of subjects will be 
missin g primary endpoint assessment s due to technical issues /low-quality  of the  diagnostic 
pulmonary CTA images , procedural mortality,  withdrawal,  or refusal to continue participation  in 
the study or lost to follow -up. Patients missing primary endpoint assessments due to los t to 
follow -up are accounted for in the sample size calculation.  
 
11.8 SENSITIVITY ANALYSIS  
Sensitivity analyses may be performed on the primary  efficacy and primary safety endpoints to describe 
the potential impact of missing data on the observed study results. Subjects missing the primary  efficacy 
endpoint and/or primary safety endpoint will be imputed using best -case  and worst -case analyses. For 
subjects missing the primary efficacy endpoint, best -case imputation will use the best ob served change 
in RV/LV ratio at 48 hours post procedure in the study population. Worst -case imputation of the primary 
efficacy endpoint will use the worst observed change in RV/LV ratio at 48 hours post procedure in the 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
41 
CONFIDENTIAL   
 study population. For subjects missi ng the primary safety endpoint, meaning they did not have a 48-hour  
visit, best -case imputation will assume the subject did not experience an MAE within the first 48 hours 
after the procedure. Worst -case imputation of the primary safety endpoint will assum e the subject did 
experience an MAE within the first 48 hours after the procedure. Further, a tipping point analysis may be 
performed to assess sensitivity without need for postulating a specific set of assumptions regarding 
missing data. If there is evide nce of non -normality of the primary efficacy endpoint based on a Shapiro -
Wilk test at the 0.05 alpha level, a non -parametric sign test will be used .  
11.9 POOLABILITY OF DATA  
This study is designed and conducted as a multicenter clinical trial. All participatin g sites will be selected 
using the same criteria and trained prior to enrolling subjects. All subjects will be treated and evaluated 
following the same protocol to ensure generalizability of the study results. Poolability of the data across 
centers in a mu lticenter study is assumed without burden of proof.  
Nevertheless, poolability of data across sites will be examined for apparent violation of the poolability 
assumption. A logistic regression on the primary safety endpoint and a linear regression on the pr imary 
efficacy endpoint will be used to confirm the pooling of data across sites. For each regression model, a 
test for fixed site effect at the 0.15 alpha level will be used to assess potential heterogeneity. If there is 
evidence of heterogeneity of sites , a random site -effect model will be used to summarize the associated 
endpoint. The results of the poolability analysis will be used to assess the robustness of study results, not 
to change the study conclusion. Sites with fewer than five subjects will be combined and treated as a 
single site for these analyses.   
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
42 
CONFIDENTIAL   
  
12 DATA  QUALITY  ASSURANCE  
A database  will be overseen  for this study  in accordance  with  regulatory  data  integrity  requirements,  
the Data  Management  Plan  (DMP),  and SOPs.  All data  elements  for all subjects  will be collected  using  
electronic case report forms (eCRFs). In addition, electronic source data, meaning source data  
originally  captured  in electronic  format,  maybe  used  to populate  eCRF  data  fields  where  it is possible  
to reduce unnecessary duplication of data and to reduce the possibility of transcription errors. All  
eCRF  data  fields  that have  data  that is transmitted  from  electronic  source  data  will have  an attached  
and auditable Date Element Identifier in accordance with the Gu idance for the Industry: Electronic  
Source Data in Clinical Investigations (September 2013). Data will be entered into the eCRFs at  
baseline, index procedure, 48 – hours, hospital discharge and 30 days after the index procedure.  Data 
will be reviewed for accuracy and completeness by the sponsor or designee during all onsite  and 
remote monitoring visits and throughout the data management process. Any discrepancies will  be 
resolved  with  the clinical  investigator  or designee,  as appropriate.  Acce ss to the database  shall  be 
limited  to appropriate  trained  personnel in  order  to preserve data  integrity.  
12.1 DATA  MANAGEMENT  
The standard  procedures  for handling  and processing  records  will be followed  per GCP and the 
SOPs.  
For the duration of the study, the investigator and their delegates will maintain complete and  
accurate  documentation,  including  but not limited  to, medical  records,  study  progress  notes,  
laboratory  reports,  signed  subject  informed  consent  forms,  correspondence  with  the reviewing  IRB, 
correspondence  with  the sponsor  or sponsor’s  designee  and Study  Monitor,  adverse  event  reports,  
and information  regarding  subject  discontinuation  or completion of the study. For each enrolled 
subject, images will be appropriately de -identifi ed, and  sent to  the imaging  Core Lab  for evaluation.  
The investigator/institution will permit direct access to source data and documents in order for  
study -related monitoring, audits, IRB reviews, event adjudication and regulatory inspections to be  
perform ed. The investigator will obtain, as part of the informed consent process, permission for  
authorized sponsor employees, study monitors or regulatory authorities to review, in confidence,  
and records  that identify subjects  in this trial.  
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
43 
CONFIDENTIAL   
  
 
12.2 CONFIDENTIALITY  OF DATA  
Information about study subjects will be kept confidential and managed according to the  
requirements  and regulations  of the local  and national governing  bodies.  
All data and information collected during this study will be considered confidential by the sponsor  
and their  delegates.  All data  used  in the analysis  and summary  of this study  will be anonymous,  and 
without reference to specific subject names. Access to subject files will be limited to authorized  
personnel of the sponsor and sponsor’s designee, the investigator, clinical site research staff and  
authorized regulatory authorities. Authorized regulatory personnel have the right to inspect and  
copy  all records  pertinent  to this study.  
 
12.3 SOURCE  DOCUMENTS  
Source data is all information, original records (and certified copies of original records) of clinical  
findings, observations, or other activities in a clinical trial necessary for the reconstruction and  
evaluation of the trial. Source data are contained in source docum ents (original records or certified  
copies). Examples of these original documents and data records include but are not limited to the  
following:  hospital  records,  clinical  and office  charts,  laboratory  notes,  memoranda,  subjects’  diaries  
or evaluation  checklists,  recorded  data  from  automated  instruments,  copies  or transcriptions  
certified after verification as being accurate and complete, microfiches, photographic negatives,  
microfilm  or magnetic  media,  subject  files,  and records  kept  at the pharmacy,  and at the laboratories  
involved  in the clinical  trial.  
Data will be entered into the eCRF using direct entry of data into the eCRF. For all data, the eCRF  
will be capable  of recording  metadata  as data  element  identifiers  (DEIs)  that will  identify  the: 
1. Originators  of the data  element  (including  those  entered  manually  (e.g.,  by the clinical  
investigator(s))  or automatically by  devices  
2. Date  and time  that the  data  element  was entered  into the eCRF.  
 
These data element identifiers allow sponsors, FDA, and other authorized parties to examine the  
audit trail of the eCRF data and to provide information that will allow FDA to reconstruct and  
evaluate  the clinical  investigation.  All data  entered  in the eCRF , either  directly  or originating  from  an 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
44 
CONFIDENTIAL   
  
electronic system will be available for review and updates by the investigator and not be final until  
electronically  signed  by the  investigator.  
Regulations require that the investigator maintain information in the subject’s medical records  
that corroborate data collected for the study. To comply with these regulatory requirements, at a  
minimum,  the following is  a list of information  that should  be maintained.  
• Medical history/general physi cal condition of the subject before involvement 
in the  study of a sufficient nature to verify the clinical investigational plan (CIP) 
eligibility  criteria  
• Dated and signed study/progress notes on the date of entry into the study 
documenting  the following:  
o The general  health  of the subject  
o The discussion  of the study  risks  and benefits  with  the subject  
o Completion  of the informed  consent  process  
o A statement  the subject  reviewed  and signed  the subject  
informed  consent  form  
• Dated  and signed  notes  from  each  subject  visit to support  all data  
recorded  on the eCRFs  
o Adverse Events reported and their continuation or resolution at each visit,  
including supporting documents such as discharge summaries, lab results, non - 
invasive  testing  reports  
o Notes  regarding  CIP-required  and prescription  medications  taken  during  the 
study  (including start  and stop  dates if  known)  
o Subjects general health and medical condition upon completion of or  
withdrawal  from  the study.  
 
12.4 ELECTRONIC  CASE REPORT  FORMS  
The eCRFs  contain  confidential  material.  Specific  instructions  to complete  the eCRFs  will be 
provided  to the clinical investigator and other site personnel as appropriate. The clinical 
investigators or  designees  are responsible  for reporting clinical  study  requested  information  in the 
eCRFs.  
 
 
12.5 RECORD RETENTION  
FDA regulations  require  that all study  records,  including  those  retained  by the Site Institution,  need  
to be retained for a period of two years following the date a marketing application is approved for  
the drug for the indication for which it is being investigated; or, if no application is to be filed or if  
the application is not approved for such an indication, until 2 years after the investigation is  
discontinued  and FDA is notified  or as otherwise  stated  in the signed  clinical  trial agreement.  
The investigator  will retain  study  essential  documents  for a minimum  of 2 years  after  formal  closure  
of the trial.  These  documents  must  be retained  for a longer  period  if required  by an agreement  with  
the sponsor or sponsor’s designee or defined by local or national regulations. The sponsor or  
sponsor’s designee will inform the investigator/institution as to when these documents no longer  
need  to be retained.  All clinical  sites  will maintain  all records  pertaining  to this study  for a minimum  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
45 
CONFIDENTIAL   
  
of 2 years  after the study  is discontinued.  The sponsor  or sponsor’s  designee  will notify  the clinical  
sites  of the date  of discontinuation.  
 
 
12.6 CLINICAL  DATA  MONITORING  PROCEDURES  
Clinical Research Associates (CRAs) will conduct site visits at the study facilities to monitor the  
study  in compliance with  the CIP, SOPs,  GCP,  ISO 14155  and the Monitoring Plan.  
Monitoring visits will occur as defined in the Monitoring Plan and/or as required to conduct t he 
study.  The clinical  study  center  agrees  to allow  these  monitors  and other  authorized  AngioDynamics  
personnel access to information and clinical supplies related to the study. CRAs will verify data  
entered into the CRFs against hospital records or other source documents to ensure accuracy and  
completeness of the CRFs for each subject. Clinical investigators and their staff agree to assist the  
monitors in their activities. Requests may be made to review subject charts by the sponsor or  
sponsor’s  designee  so that CIP adherence  and source  documentation  can be verified.  
Monitoring visits will be performed at regular intervals throughout the course of the study to  
ensure compliance with the CIP. Monitoring activities may include, but are not limited to th e 
following:  
• Evaluation  of subject  screening  and selection  methods  
• Verification  of signed  informed  consent  for each  subject  
• Verification of source documentation against completed case report forms for each  
subject  
• Assurance  that required  study  reports,  including  reports  to the applicable  IRB, are 
generated  in a timely  manner  
• Monitoring  of Safety  Events,  including  device  deficiencies  that could  have  led to SAE 
• Monitoring  of device  deficiencies  irrespective  of associated  safety  events  
• Review  of clinical  investigation  plan  deviations  
• Overall  study  compliance  
• Review  of the investigator  site file. 
 
13 INVESTIGATOR  AND  SPONSOR  RESPONSIBILITIES  
13.1 INVESTIGATOR RESPONSIBILITIES  
The investigator  is responsible  for the conduct  of the  study  at the site.  Prior  to shipment  of 
the first investigational  device  and first procedure,  the investigator  must  do the following:  
• Read  and understand  the CIP; 
• Sign and complete  the Investigator’s  Agreement;  
• Provide  an accurate  financial  disclosure,  and file an update  annually  and 1 year  
after  the completion  of the study;  
• Ensure  appropriate  IRB and institutional  approvals  are in place  prior  to 
completing  any portion  of the informed  consent  process  or permitting  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
46 
CONFIDENTIAL   
  
subject  participation;  
• Complete  and file a fully  executed  clinical  trial agreement  between  
sponsor  or sponsor’s  designee,  investigator,  and institution  (as 
applicable);  and 
• Provide  assurance  of completed  training  on the investigational  
device and procedures being studied under the clinical investigation  
plan.  
In addition, each investigator must  have  written approval by the sponsor or sponsor’s  
designee  to either  use the investigational  device  being  studied  under  this clinical  
investigation  plan  and/or  perform  the procedure  being studied.  
The study will be conducted in compliance with all relevant portions of 21 CFR Part 50 and  
56: The study  will be overseen  by an IRB and all subjects  will be consented.  An IDE application 
in compliance with 21 CFR 812 will be submitted to FDA and approved prior to  commencing 
the study. The study also complies with HHS’ Policy for Protection of Human  Research  
Subjects  45 CFR 46.  
Throughout  the course  of the study,  it is the investigator’s  responsibility  to ensure  that the 
investigation is conducted according to the signed Investigator’s Agreement, the  CIP, all 
applicable  national  and local  regulations,  and the respective  IRB requirements,  
specifically:  
• Protecting  the rights,  safety,  and welfare of  subjects  under  the investi gator's  care  
• Controlling  devices  under  investigation  
• Ensuring  that informed  consent  is obtained  from  each  subject  in 
accordance  with  21 CFR Part 50/ISO 14155.  
Under no circumstances may an investigator provide an investigational device AlphaVac  
Multipurpose  Mechanical  Aspiration  (MMA)  F1885 PE for use to any person  who  has not 
received  training  for use from  the sponsor  or sponsor’s  designee.  
Upon  completion  or termination  of a clinical  investigation  or the investigator's  part of an 
investigation, or at the sponsor's request, an investigator shall control the device as the 
sponsor  directs.  
13.1.1  DEVIATIONS  FROM  INVESTIGATIONAL  PLAN 
 
A CIP deviation  is defined  as an event  where  the clinical  investigator  or site personnel  deviate  from  
the CIP or study procedures. It is the investigator’s responsibility to ensure that there are no  
deviations from the clinical investigation plan. An investigator may deviate from the CIP without  
prior  written  approval  from  the sponsor  or sponsor’s  designee  in cases  of medical  emergencies  to 
protect  the life or physical  well-being  of a subject  in an emergency.  In that event,  the investigator  
is required to notify the sponsor and the applicable IRB as soon as possible, but in no event later  
than 5 working days after the emergency occurred, of the deviation from the CIP by the Sponsor  
is required for changes in/or deviations from the CIP. Additionally, if these changes or deviations  
may  affect  the scientific soundness  of the plan  or the rights,  safety,  or welfare  of human  subjects,  
FDA and IRB notification  is also required.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
47 
CONFIDENTIAL   
  
Prior  approval  is generally  not expected  in situations  where  unforeseen  circumstances  are beyond  
the investigator’s control (e.g., the subject was not available for a scheduled follow -up office visit  
or has moved without providing a forwarding address). These  events, although outside the  
investigators control, are still required to be reported on the appropriate CIP deviation CRF in  
order  to ensure  that all deviations  from  the standard  subject  population  are adequately  
documented and reported. The investigator will inform the sponsor or sponsor’s designee of all  
deviations,  and the reviewing  IRB of all CIP deviations  as per the IRB requirements  for this study.  
 
If the sponsor or sponsor’s designee becomes aware that an investigator is not complying with  
any part of the CIP, including the signed Investigator’s Agreement, the CIP, or any conditions of  
approval  imposed  by the reviewing  IRB, the sponsor  or sponsor’s  designee  will immediately  secure  
compliance, and may suspend the investigator’s participation (including enrollment at the site),  
and may  discontinue  shipments/use  of the device  to the investigator  until  compliance  is achieved  
and guaranteed. The sponsor may terminate an investigator’s participation in the study at its  
discretion.  
 
 
13.1.2  MAINTAINING  RECORDS  
The investigator  will maintain  the following  accurate,  complete,  and current  records  relating  
to the investigator's  participation  in an investigation:  
1. Correspondence  with  another  investigator,  an IRB, the sponsor,  a monitor,  or FDA.  
2. Records  of each  subject's  case  history  and exposure  to the device,  including:  
o documents evidencing informed consent and, for any use of a device  
by the investigator  without  informed consent,  
o any written  concurrence  of a licensed  physician  and a brief  description  
of the circumstances  justifying  the failure to obtain  informed  consent  
o all relevant  observations,  including  records concerning  ADE 
(whether  anticipated or not),  
o information and data on the condition of each subject upon entering,  
and during the course of, the investigation, including information  
about  relevant  previous  medical  history  and the results  of all 
diagnostic  tests,  
o a record of the exposure of each subject to the investigational device,  
including  the date and  time of  each  use, and any other  therapy,  
3. The CIP, with documents showing the dates of and reasons for each deviation  
from  the CIP, 
4. Any other  records  that FDA requires  to be maintained  by regulation  or by specific  
requirement  for a category  of investigations  or a particular  investigation.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
48 
CONFIDENTIAL   
  
13.1.3  SUBMITTING  REPORTS  
In compliance with local and national laws, each investigator may be required to prepare and  
submit complete, accurate, and timely reports to the sponsor or sponsor’s designee and the  
FDA/IRB.  These  reports  may include:  
1. Any UADE occurring during an investigation. (No later than 10 working days after  
the investigator  first learns  of the effect.)  
2. Any deviation from the investigational plan made to protect the life or physical well - 
being of a subject in an emergency as soon as possible, but no later than 5 working  
days after the emergency occurs. Except in emergency situations, a CIP devi ation  
requires  prior  sponsor  approval;  and if the deviation  may  affect  the scientific  
soundness of the plan or the rights, safety, or welfare of subjects, prior FDA and IRB  
approval  are required.)  
3. Any use of the device  without  obtaining  informed  consent.  (Due  within  5 working  
days  after  such use.)  
4. Any further information requested by FDA or the IRB about any aspect of the  
investigation  
The investigator  will provide  in writing  any withdrawal  of IRB approval  of the study  or an 
investigator  within  5 working days  of such  action.  
 
 
13.2 SPONSOR  RESPONSIBILITIES  
 
13.2.1  GENERAL  DUTIES  
The sponsor has the overall responsibility for the conduct of the study including assurance that the  
study satisfies the regulatory requirements of the appropriate regulatory agencies, ensuring IRB  
approvals, selecting investigators, ensuring proper monitoring, and ensuring informed consent is  
obtained. The sponsor will ensure oversight of the CRO according to local and national regulations.  
The sponsor w ill provide all information necessary to conduct the study, including the CIP, and any  
reports of prior investigations as appropriate. During the conduct of the clinical study, updates in  
information  that may  impact  the clinical  study  will be made  availabl e to all the appropriate  national  
and local  regulatory authorities.  
The sponsor will submit IDE progress reports to FDA at 6 -month intervals.  
 
 
13.2.2  SELECTION  OF INVESTIGATORS  
The sponsor  will select  investigators  qualified  by training  and experience.  Sites  will be selected  based  
upon a site assessment, appropriate facilities, clinical experience, and the qualifications of the  
Principal  Investigator.  Investigators  will be evaluated  by the sponsor  based  on the following:  
1. A curriculum  vitae,  or other statement  of investigator’s  relevant  training  and experience  
including  type  of experience  with  the intended  procedure  and clinical  research,  specifically;  
2. Education  and experience  in the management  of pulmonary  embolism;  
3. Whether the investigator  has an adequate subject  population  to meet  requirements  of the 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
49 
CONFIDENTIAL   
  
study;  
4. Whether the investigator has adequate time to be personally involved in the conduct of the  
study,  and adequate  research  staff  and resources to  support  the study;  
5. Whether  the investigator’s  study  center  is associated  with  an IRB that satisfies  all 
applicable  regulatory  requirements;  and 
6. Whether an investigator was involved in an investigation or other research that was  
terminated, an explanation of the circumstances that led to the termination must be  
provided.  
Prior  to site initiation,  each  investigator  must  also submit  the following:  
7. A certificate  of human  subject’s  protection  training  (if required  by reviewing  IRB) 
8. A completed  financial  disclosure  form  (and  annually  up to one year  after  the completion  of 
the study)  
9. A signed  Investigator’s  Agreement  indicating  an investigator’s  commitment  to: 
o Conduct  the investigation  in accordance  with  the agreement,  the CIP, Parts  50, 
56, and 812,  and any conditions  of approval imposed  by the IRB or  FDA;  
o Supervise  all testing  of the device  involving  human  subjects;  
o Ensure  that the requirements  for informed  consent  are met consistent  with  
21 CFR Part  50/ISO:14155;  
o Conduct  the study  according  to the CIP. 
The sponsor  reserves  the right  to apply  additional  criteria  to site and/or  investigator  selection.  
13.2.3  TRAINING  
Training may consist of a review of the IFU, hands -on training on the device, presentations,  
literature, etc. The training program will be standardized and will be documented. Additional  
training will include a review of the CIP, the regulations for medical device investigations and  
general  study logistics  required to  complete the  study.  
Training  of appropriate  clinical  study  personnel  will be the responsibility  of the sponsor  or sponsor’s  
designee. To ensure uniform data collection and CIP compliance the sponsor or sponsor’s designee  
will review the CIP (including the informed consent form), techn iques for identification of eligible  
subjects,  instructions  on data  collection,  methods  for scheduling  follow -up visits  in the window,  etc. 
Detailed feedback regarding completion of the eCRFs, study requirements, and CIP compliance will  
be provided by  the sponsor, CRO,  and/or  its Study Monitors  as appropriate.  
13.2.4  CHANGES  IN THE CLINICAL  INVESTIGATIONAL  PLAN 
The sponsor will obtain FDA approval for any change to the CIP that may affect the scientific  
soundness  of the investigation  or the rights,  or the rights,  safety  and/or  welfare  of the subjects.  
Approved CIP  amendments will be provided to the investigators by the sponsor or sponsor’s  
designee prior to implementing the amendment. The investigator will be responsible for notifying  
the reviewing IRB of t he CIP amendment (administrative changes) or obtaining IRB approval of the  
CIP amendment (changes in subject care of safety), according to the instructions provided with the  
CIP amendment. The IRB acknowledgement/approval of the CIP amendment must be docum ented  
in writing prior to implementation of the CIP amendment. Copies of this documentation must be  
provided  to the sponsor  or sponsor’s  designee.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
50 
CONFIDENTIAL   
  
13.2.5  WITHDRAWAL  OF FOOD  AND  DRUG  ADMINISTRATION  APPROVAL  
The sponsor  will notify  all reviewing  IRBs  and participating  investigators  of any withdrawal  of FDA 
approval of the investigation and shall do so within 5 working days after receipt of notice of the  
withdrawal  of approval.  
14 ETHICS  AND  REGULATORY  COMPLIANCE  
 
14.1 CONDUCT OF  THE CLINICAL  STUDY  
Requires  review  from  the regulatory  affairs  representative  on the document  development  
committee. Conduct of the clinical study will follow standard operating procedures (SOPs) from  
AngioDynamics  and the CRO,  as well as the Code  of Federal  Regulations,  the Declaration  of Helsinki,  
GCP, and other national and local laws. Each investigator must sign and date the Investigator’s  
Agreement prior to the start of this study. With the signature, the investigator agrees to perform all  
study  procedures  according  to the governing  local  and national regulations,  and the CIP. 
An independent CEC will be established to review and adjudicate all clinical study endpoints as  
defined  in the CIP. 
14.2 CONFLICT  OF INTEREST  
If the FDA believes that the financi al interest of any investigator raises a serious question about  
the integrity  of the data,  the FDA may  take  any action  it deems  necessary  to ensure  the reliability  
of the data  including:  
• Initiating  agency  audits  of the data  derived  from  the clinical  investigator  in question  
• Requesting  that the applicant  submit  further  analyses  of data,  e.g.,  to evaluate  the 
effect of  the clinical  investigator's  data  on the overall  study  outcome  
• Requesting  that the applicant  conduct  additional  independent  studies  to confirm  the 
results  of the questioned  study  
• Refusing  to use the data  from  the covered  clinical  study  as the primary  basis  for an 
agency  action,  such  as 510(k)  clearance.  
 
Therefore,  any investigator  (or sub-investigator),  their  spouses,  and/or  dependent  children  who  has 
a potential  conflict  of interest  with  this study  (patent  ownership,  royalties,  or financial  gain  greater  
than the minimum allowable by their institution, etc.) must have the conflict evaluated by the  
sponsor.  If a financial  interest  appears  to exist,  a management  plan  should  be generated  to minimize  
bias and must  be approved by  the study sponsor  prior  to participation  in this study.  
 
14.3 INSTITUTIONAL  REVIEW  BOARD  
A properly  constituted,  valid  IRB must  review  and approve  the CIP, the informed  consent  form,  and 
related subject information  and recruitment materials  before the  start of the study.  It is the  
responsibility  of the investigator  to obtain  approval  of the CIP from  the institution’s  IRB and to keep  
the IRB informed of any SAEs or SADEs and amendments to the CIP. Additional requirements  
imposed  by the IRB/EC  or other  regulatory  authority  shall  be followed  if appropriate.  All 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
51 
CONFIDENTIAL   
  
correspondence  with  the IRB should  be filed  by the investigator  and copies  sent  to the sponsor  or 
sponsor’s  designee(s).  
14.4 CLINICAL  STUDY  INFORMED  CONSENT  APPROVAL  
Informed consent shall be obtained in writing and documented before a subject is enrolled in the  
clinical  study  in accordance  with  the principles  of Informed  Consent,  according  to the Declaration  of 
Helsinki, Good Clinical Practice (GCP), 21 Code of Federal Regulations (CFR) Part 50, the Medical  
Devices  Directive  93/42/EEC,  and Interna tional  Organization  for Standardization  (ISO)  14155 -. 
It is the responsibility  of the clinical  investigator  to ensure  that written  informed  consent  is obtained  
from  the subject  (or legally  acceptable  representative)  before  any activity  or procedure  is 
undertaken that is not part of routine care. Information obtained during the conduct of the clinical  
that may impact the subject informed consent may require revisions to the informed consent. If so,  
revisions and approvals of such changes by the appropriate regulating authority are required.  
Documentation of the current versions of the informed consent shall be documented in the clinical  
study  trial master  file (TMF).  
14.5 SUBJECT  IDENTIFICATION  AND  CONFIDENTIALITY  
Subject identification and confidentiality will be ensured according to the terms and definitions in  
21 CFR Parts  50, 56 and 812/ISO  14155.  This includes  but is not limited to  the following:  
• Subjects  will be identified  on all CRFs  and source  documents  by a unique  
identification  reference that  may include  the subjects’  initials  
• CRFs are confidential documents and will only be made available to the sponsor or  
sponsor’s designee, the clinical investigator, the biostatistician, the CEC, and if  
requested,  to advisory  committees  and regulatory  authorities  (including  FDA)  
• Data will be stored and analyzed by computer following national regulations for  
handling of  computerized  data  
Each study center will maintain (anonymous to AngioDynamics) a list identifying all subjects  
entered  into the trial.  The list will be  maintained  as part of the investigation  file. 
This study  will be conducted  according  to the US FDA standards  of Good  Clinical  Practice  (FDA  Title  
21 Code  of Federal  Regulations  Part 11, 50, 54, 56 and 812),  ISO: 14155,  the Declaration  of Helsinki,  
and the ICH Guidelines.  
14.6 SITE QUALIFICATION  VISIT 
A site qualification visit will be performed to evaluate site facilities, investigator qualifications, and  
site knowledge of  Good  Clinical  Practi ce (GCP)  guidelines.  
14.7 SITE INITIATION  VISIT 
As available,  study  personnel  will participate  in a site initiation  visit.  Training  will be provided  to all 
applicable personnel not able to attend the site initiation visit. Components of this initiation visit  
may  include:  
• Introduction  of the study  design  including  the treatment and  follow -up phase  
• Product  training  to all end-users  
• CRF completion  training  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
52 
CONFIDENTIAL   
  
• Safety  reporting  instructions  
• Training  on the regulations  governing  human  research  
14.8 INSURANCE  
 
The sponsor  shall  maintain  insurance  coverage  for this study.  Pertinent  information  regarding  the 
coverage  shall  be made  available to  the site upon  request.  
14.8.1  IMPACT ON MEDICARE BENEFICIARIES  
It is widely understood that the risk of  venous thromboembolism and the potential for pulmonary 
embolism increases with age. While clinical data indicate that most cases of PE occur at 60 to 70 
years of age, autopsy data show the highest incidence among individuals 70 to 80 years of age.16 
“This increasing risk is associated with a concurrent enhancement of coagulation activation and 
gradual development of a 'prethrombotic state'. This is reflected by increased levels of coagulation 
activation peptides in the elderly, as well as decreased ac tivity of the fibrinolytic system. Moreover, 
with increasing age there is an increased incidence of comorbid conditions, which may, in 
themselves, be associated with an increased risk for the development of thrombosis. Accurate 
diagnostic techniques and st rategies for treatment and prevention of deep vein thrombosis (DVT) 
are mandatory in order to prevent potentially fatal complications of DVT, such as pulmonary 
embolism.” 17 
Further, in the past 18 months, the United States has seen that elderly patients are some of the 
most impacted by COVID -19.  While vaccinations to prevent or mitigate the impact of COVID -19 are 
now available and a large percentage of Medicare beneficiaries are vaccinated, the medical 
community continues to learn about long -term effects of exposure to COVID -19 and about long -
term efficacy of the vaccines as variants of the SARS COVID -19 virus are identified.   What is clear in 
peer reviewed clinical literature is that there is a “link between COVID -19 and thrombotic 
complications , including a high incidence of acute PE and venous thromboembolism (VTE).”1 
While Medicare is likely aware of thromboembolism risks for beneficiaries, heretofore, no study of 
this population has sought to identify potential healthcare disparities and soci al needs of the 
patients who develop pulmonary embolism. This study includes administration of Medicare’s 
Accountable Health Communities Standardized Screening for Health -related Social Needs in Clinical 
Settings.18 The findings of the screening will not o nly help identify individual patient social needs 
that may be addressed by provider referral to local services, but this clinical trial will summarize the 
finding across the enrolled populated to inform medical professional about the potential healthcare 
disparities and health -related social issues faced by patients treated for pulmonary embolism.  
 
14.9 SITE AUDITS  
There may be inspection and audits by government regulatory authorities, applicable compliance,  
and quality  assurance  offices.  If these  are requested , the investigator  and study  site personnel  must  
be available  to respond  to reasonable  requests  and queries  made  by authorized  regulatory  
representatives  during  the audit  process.  If so requested,  the investigator  must  provide  the sponsor  
or sponsor’s designee with copies of all correspondence that may affect the review of the current  
study  or their  qualification  as an investigator  in clinical  studies  conducted  by the sponsor.  
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
53 
CONFIDENTIAL   
 14.9.1  INTERNAL  AUDITS  BY SPONSOR  OR SPONSOR’S DESIGNEE  
In accordance wit h local  and national regulations and  the sponsor’s or sponsor’s designee’s  
operating procedures, the sponsor or sponsor’s designee may request access to all study records,  
including  source  documents,  for inspection.  The investigator  will ensure  the capability  for 
inspections of applicable study -related facilities (e.g., cardiac catheterization laboratory, surgery  
suite,  diagnostic  laboratory.)  
Internal quality assurance audits will be conducted at various sites during the trial. Selection of  
sites  to undergo  auditing  will be determined  by the sponsor  per a pre-established  audit  plan.  
 
14.10  EXTERNAL  AUDITS  
Requests by regulatory agencies to inspect the study sites may be made as well. The investigator or  
designee is required to report to the sponsor or sponsor’s designee as soon as possible after  
receiving a request from and regulatory authority to perform an audit. The clinical investigator  
agrees  to allow  inspectors  from  regulatory  agencies  to review  records  and to assist  the inspectors  in 
their  duties , if requested.  
 
14.11  PUBLIC  DOMAIN ACCESS  TO THE CLINICAL  STUDY  
A description  of this clinical  trial will  be available  on http://www.ClinicalTrials.gov , as required  by 
US Law.  Information regarding  public  access will be presented  in the  informed  consent,  as 
required  by US Law.  
 
15. GENERAL  CONSIDERATIONS  
 
15.1 DISCONTINUATION  OF THE STUDY  
The study may be suspended or discontinued early if there is an observation of SAEs presenting an  
unreasonable risk to the study participants, inadequate subject enrollment, or determination that  
no statistically significant  result can  be obtained.  
 
The sponsor  may  terminate  investigator  and site participation  in the study  if there  is evidence  of an 
investigator’s  failure  to maintain  adequate  clinical  standards  or evidence  of an investigator  or staff’s  
failure  to comply with  the CIP. 
Notification of suspension or termination will occur no later than 5 working days after the sponsor  
makes  the determina tion.  In the event  of study  suspension  or termination,  the sponsor  or sponsor’s  
designee will send a report outlining the circumstances to the reviewing IRB the appropriate  
regulatory agencies, and to all participating investigators. Any suspension or termination may not  
be re-initiated without prior  approval  of the IRB and  sponsor.  
AngioDynamics reserves the right to discontinue this study for safety or administrative reasons at  
any time . 
15.2 USE OF INFORMATION  AND  PUBLICATIONS  
All information  concerning  the AlphaVac  Multipurpose  Mechanical  Aspiration  (MMA) F1885 PE, 
AngioDynamics  operations,  patent  applications,  manufacturing  processes,  and basic  scientific  data  
supplied  by AngioDynamics  or the CRO  to the clinical  investigator  and not previously  published, are 
considered confidential and remains the sole property of AngioDynamics. This  includes  all study 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
54 
CONFIDENTIAL   
 materials,  CRF forms, worksheets  and CRFs.  
The information developed in this study may be used by AngioDynamics a s support for a pre - 
market approval filing and  in connection  with the continued development and  pre-market  
approval of the System. Any publication or other public presentation of the AlphaVac MMA  F1885 
PE data resulting from this study will require prior review and written  approval  of AngioDynamics.  
At the conclusion of the study, it is expected that the sponsor/investigators will promptly prepare  
and submit  a multi -center  manuscript  for publication  in a reputable  scientific  journal.  The publication  
of the principal results (including abstracts) from any single site experience within the study is not  
allowed until the preparation and publication of the multi -center results. Exceptions to this rule  
require the prior written approval of the sponsor. The results of this study are intended to be  
published in a peer -reviewed journal. No individual investigator may publish on the results of this  
study,  or his/her  own  patients,  without prior  approval  from  the Sponsor.  
No participating physician may publish or present on the results of this study, or study data on  
his/her  own  patients,  without  prior  approval  from  the Sponsor.  If after  180 days  from  the conclusion  
of the study, the Sponsor has not published the results, the investigators may publish without prior  
approval from the Sponsor. This includes the release of negative outcomes and if the study is  
terminated  early results  will be hastened.  
Further analyses, beyond those presented in the initial multi -center publication may be propo sed 
to the sponsor. Many secondary manuscripts are anticipated. For purposes of timely abstract  
presentation and publication, such secondary publications may be delegated to the appropriate  
principal  authors;  however,  any final  analyses  and manuscript  review  for all multi - center  data  will 
require  the prior  written approval of  the sponsor.  
None of the results, in whole or in part, of the study carried out under this CIP, nor any of the  
information provided by the sponsor for the purposes of performing the study, will be published or  
passed  on to any third  party  without  the consent  of the study  sponsor.  Any investigator  involved  with  
this study is obligated to provide the sponsor with complete test results and all data derived from  
the study.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
55 
CONFIDENTIAL   
  
16. APPENDIX I: STUDY  DEFINITIONS  
 
BLEEDING  
Loss of blood from the vascular system. Bleeding was classified by the GUSTO15(Global Utilization of  
Streptokinase  and Tissue  Plasminogen  Activator  for Occluded  Coronary  Arteries)  bleeding  criteria:  
 
• Major  Bleeding  includes  GUSTO  Severe/life  threatening  and moderate  categories:  
o GUSTO  Severe:  
▪ Intracranial  Hemorrhage  
▪ Fatal/life  threatening  bleeding  
▪ Resulting  in substantial  hemodynamic  compromise  requiring  intervention  
o GUSTO  Moderate:  
▪ Requiring  blood  transfusion  but did not result  in hemodynamic  compromise  
• Minor  Bleeding  includes  GUSTO  Mild  bleeding:  
o GUSTO  Mild  bleeding  that does  not meet  above  criteria  
 
CARDIAC  INJURY  
The following  events  are examples  of possible  cardiac  injury:  
 
• Acute  heart  failure  
• Acute  myocardial  infarction  
• Arrhythmia  requiring  intervention  • Cardiac  hematoma  
• Tricuspid  or Pulmonic  valve  damage  
• Pericardial Effusion  
 
CLINICAL  DETERIORATION  
Also  referred  to as hemodynamic  collapse14 is defined  as having  one of the following:  
• need  for cardiopulmonary  resuscitation,  intubation,  vasopressors,  ECMO/ECLS;  or systolic blood  pressure  
(SBP)<90  mm Hg for at least 15  mins,  or 
• drop of SBP by at least 40 mm Hg for at least 15 minutes with signs of end -organ  
hypoperfusion  (cold  extremities  or low urinary  output<30  mL/h  or altered  mental  status);  or 
• need  for catecholamine  administration  to maintain  adequate  organ  perfusion  and SBP>90  
mm Hg (including  dopamine  at the rate of  >5 micrograms/kg  per minute).  
 
COMPLICATIONS   
An undesirable  clinical  event  that could result  in Air Embolism, Cardiac Arrhythmia, Arteriovenous Fistula, Blood 
Loss/Blood Trauma, Bradycardia, Tachycardia, General Discomfort, Tenderness, or Pain, Hemorrhage, Infection (Local 
or Systemic), Pleural Effusion,  Pericardial Effusion,  Pulmonary Embolism, Pulmonary Infarction, Pulmonary Artery 
Injury/Wire Perforation, Damage to Blood Vessel, Distal Embolization, Hematoma, Vascular Thrombosis, Cardiac  Valve 
Injury, Cardiac Perforation, Vessel Spasm, Hemoptysis, Death. Complications may or may not be related to the 
investigator product(s).  
 
DEEP  VEIN  THROMBOSIS  
A clot in  a vein  deep  under  the skin usually  in a leg. 
 
DISSECTION  
Angiographic evidence  of a tear in the arterial  wall as defined  by the occurrence  of intramural  
hematoma.  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
56 
CONFIDENTIAL   
  
DISTAL  EMBOLIZATION  
Migration  of a filling  defect or  thrombus  to distally  occlude  the target  vessel  or one of its branches.  
 
ECMO  
Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life support (ECLS), is a  
means  of providing  both  cardiac  and respiratory  support  to persons  whose  heart  and lungs  are unable  
to provide an  adequate amount of  gas exchange to  sustain  life. 
 
EMBOLI  
Blood  clots  or thrombi  transported  by blood  from  a distant  source.  
 
PERFORATION  
The piercing  or rupturing  of a blood  vessel;  perforations can  be detected  or observed  angiographically.  
 
PULMONARY  EMBOLISM  
A blood  clot that dislodges  and travels  to the lungs  resulting  in complete  or partial  occlusion  of the 
pulmonary  arteries.  
 
LOW -RISK  PULMONARY  EMBOLISM19 
Acute  PE in  the absence  of markers  defining massive  or submassive  PE. 
 
MASSIVE  PULMONARY  EMBOLISM19 
Acute  PE with  presence  of one of the following  findings:  
• Sustained  hypotension  (systolic  BP <90 mm Hg for 15 min  or requiring  ionotropic  
support)  
• Pulselessness  
• Sustained  heart  rate <40 BPM  with  signs/symptoms  consistent  with  shock  
 
SUBMASSIVE PULMONARY  EMBOLISM19 
Acute  PE with  Systolic  BP ≥90 mm Hg and RV dysfunction  or myocardial  necrosis  defined  by: 
• RV dilation  (apical  4-chamber  RV diameter  divided  by LV diameter  >0.9)  or RV systolic  
dysfunction  on CTA.  
• RV dilation  (4-chamber  RV diameter  divided  by LV diameter  >0.9)  on CT 
• Elevation of BNP (B-type natriureic peptide)  (>90 pg/mL), or N -terminal pro -BNP (>500  
pg/mL)  
• EKG changes  (new  complete  or incomplete  right  bundle  branch  block,  anteroseptal  ST 
elevation  or depression,  or anteroseptal  T-wave inversion)  
• Elevation  of troponin  I (>0.4  ng/mL)  or troponin  T (>0.1  ng/mL)  
 
RECURRENT  PULMONARY  EMBOLISM  
Symptomatic PE objectively confirmed on contrast -enhanced chest CT, ventilation perfusion  
lung  scan, or  invasive  contrast  pulmonary angiography.  
 
PULMONARY  VASCULAR  INJURY  
Pulmonary  vascular  injury  may  include  the following  events  occurring  in the pulmonary  vasculature:  
 
• Arterial Venous Fistula  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
57 
CONFIDENTIAL   
 • Dissection  
• Hemorrhage (Intrapulmonary/ Intrapleural)  
• Hemoptysis  
• Intimal flap  
• Perforation  
• Rupture  
• Thromboembolic occlusion resulting in permanent damage i.e., infarction  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
58 
CONFIDENTIAL   
 17 REFERENCES  
 
1. Standardized Screening for Health -Related Social Needs in Clinical Settings The Accountable 
Health Communities Screening Tool Alexander Billioux, MD, DPhil, Centers for Medicare & 
Medicaid Services; Katherine Verlander, MPH, Center for Medicare & Medicaid Services; 
Susan Anthony, DrPH, Center for Medicare & Medicaid Services; Dawn Alley, PhD, Center for 
Medicare & Medicaid Services May 30, 2017  
2. Circulation. 2020. Interventional Therapies For  Acute Pulmonary Embolism: Current Status  
And Principles For The Development Of Novel Evidence: A Scientific Statement From The  
American  Heart  Association.  [online]  Available  at: 
<https: //www.ahajournals.org/doi/full/10.1161/CIR.0000000000000707 >Accessed         19 
October  2020.  
3.  Emedicine.medscape.com.  2020.  Pulmonary  Embolism  (PE):  Practice  Essentials,  
Background,  Anatomy.  [online]   Available   at: 
<https://emedicine.medscape.com/article/300901 -overview>  
4.  Jan Bĕlohlávek, A., 2020. Pulmonary Embolism, Part I: Epidemiology, Risk Factors And Risk  
Stratification,  Pathophysiology,  Clinical  Present ation,  Diagnosis  And Nonthrombotic  
Pulmonary  Embolism.  [online]  PubMed Central  (PMC).  
5. Fava, M. and Loyola, S., 2003. Applications of percutaneous mechanical thrombectomy in  
pulmonary  embolism.  Techniques  in Vascular  and Interventional  Radiology,  6(1),  pp.53 -58. 
6. Becattini C, Agnelli G, Salvi A et al. Bolus tenecteplase for right ventricle dysfunction in  
hemodynamically  stable  patients  with  pulmonary  embolism.  Thrombosis  research  
2010;125:e82 - 
7. Fasullo S, Scalzo S, Maringhini G et al. Six -month echocardiographic study in patients with  
submassive  pulmonary  embolism  and right  ventricle  dysfunction:  comparison  of 
thrombolysis  with  heparin.  The American  journal  of the medical  sciences  2011;341:33 -9. 
8. Mi YH, Liang  Y, Lu YH, Li YM, Liu WX, Qian  W. Recombinant  tissue  plasminogen  activator  plus 
heparin  compared  with  heparin  alone  for patients  with  acute  submassive  pulmonary  
embolism:  one-year  outcome.  Journal  of geriatric cardiology  : JGC 2013;10:323 -9. 
9. Kucher  N, Boekstegers  P, Muller  OJ et al. Randomized,  controlled  trial of ultrasound -assisted  
catheter -directed  thrombolysis  for acute  intermediate -risk pulmonary  embolism.  Circulation  
2014;129:479 -86. 
10. Tu, T., Toma, C., Tapson, V., Adams, C., Jaber, W., Silver, M., Khandhar, S., Amin, R., Weinberg , 
M., Engelhardt, T., Hunter, M., Holmes, D., Hoots, G., Hamdalla, H., Maholic, R., Lilly, S., 
Ouriel, K. and Rosenfield, K., 2019. A Prospective, Single -Arm, Multicenter Trial of Catheter -
Directed Mechanical Thrombectomy for Intermediate -Risk Acute Pulmon ary 
Embolism.  JACC: Cardiovascular Interventions , 12(9), pp.859 -869.  
11. Goldhaber SZ, Haire WD, Feldstein ML et al. Alteplase versus heparin in acute pulmonary  
embolism: randomised trial assessing right -ventricular function and pulmonary perfusion.  
Lancet 1993;341:507 -11. 
12. Kline JA, Nordenholz KE, Courtney DM et al. Treatment of submassive pulmonary embolism  
with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double - 
blind, placebo -controlled randomized trial. Journal of th rombosis and haemostasis : JTH  
2014;12:459 -68.12.  
13. Konstantinides S, Geibel A, Heusel G et al. Heparin plus alteplase compared with heparin  
alone  in patients  with  submassive  pulmonary  embolism.  N Engl  J Med  2002;347:1143 -50.13.  
14. Meyer G, Vicaut E, Danays T e t al. Fibrinolysis for patients with intermediate -risk pulmonary  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number:  5.1 
Version  Date:  07/18/23 
59 
CONFIDENTIAL   
 embolism.  N Engl J Med 2014;370:1402 -11.14.  
15. Investigators  G. An international  randomized  trial comparing  four  thrombolytic  strategies  for 
acute  myocardial  infarction.  New  England  Journal  of Medicine  1993;329:673 –82. 
16.  Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors 
and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic 
pulmonary embolism.  Exp Clin Cardi ol. 2013;18(2):129 -138.  
17. Nurmohamed MT, Büller HR, ten Cate JW. Physiological changes due to age. Implications for 
the prevention and treatment of thrombosis in older patients. Drugs Aging. 1994 Jul;5(1):20 -
33. 
18. Barnes DH, Lo KB, Bhargav R, Gul F, DeJoy R 3rd, Peterson E, Salacup G, Pelayo J, Albano J, 
Azmaiparashvili Z, Rangaswami J, Carpio AM, Patarroyo -Aponte G. Clin Respir J. 2021 
Aug;15(8):885 -891 
19. Jaff MR, McMurtry  MS, Archer  SL, et al. Management  of massive  and submassive  pulmonary  
embolism,  iliofemora l deep  vein  thrombosis,  and chronic  thromboembolic  pulmonary  
hypertension:  a scientific  statement  from  the American  Heart  Association.  Circulation  
2011;123:1788 -830 
 
 
 
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
Version  Number: 4.00  
Version  Date: 08/15/2022  
Clinical  Investigation  Plan  Confidential  
Page  | 60 
CONFIDENTIAL   
  
18 ATTACHMENTS  
 
 
Investigator’s  Protocol  Signature  Page:  
 
 
 
CLINICAL  INVESTIGATION  PLAN  NUMBER:  2021 -EVT-01 
 
CLINICAL  INVESTIGATION  PLAN  TITLE:   
Evaluating  the Safety  and Efficacy  of the 
AlphaVac Multipurpose Mechanical Aspiration  
(MMA) F1885 PE for Treatment  of Acute 
Pulmonary Embolism.  
FINAL  CLINICAL  INVESTIGATION  PLAN:  07/18 /202 3 
 
 
I have read this clinical investigation plan and agree to conduct this clinical trial as outlined  
herein. I will ensure that all sub investigators and other study staff members have read and  
understand  all aspects  of this clinical  investigation  plan.  I agree  to cooperate  fully  with  
AngioDynamics and the CRO during the study. I will adhere to all FDA, ICH, and other applicable  
regulations  and guidelines  regarding  clinical  trials  during  and after  study  completion.  
 
Principle Investigator Name:  
 
Date:  
 
Signatur e:  
DocuSign Envelope ID: 979AA5E5-505C-4595-87F8-3B986CCAD368
  
   
 
Page 1 of 19 
 
STATISTICAL ANALYSIS PLAN  
 
Protocol Title:  Evaluating the Safety and Efficacy of the AlphaVac Multipurpose 
Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute 
Pulmonary Embolism  
Protocol Number:  2021 -EVT -01 
Protocol Version History:  Version 5.1  / 18 July 2023  
Version 5.0  / 13 June 2023  
Version 4.0 / 15 August 2022  
Version 3.0 / 22 February 2022  
Version 2.0 / 03 September 2021   
 
Investigational Product:  AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE 
  
Sponsor:  Angio Dynamics, Inc.  
  
SAP Version/Date:  1.0, 07-Dec-2023  
 
CONFIDENTIAL  
The information in this document is confidential, and its contents are the property of Angio Dynamics, Inc., 
and are confidential. Unauthorized copying , distribution, disclosure, or use is prohibited.    
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 2 of 19 
 SIGNATURE PAGE  
 
Protocol Title:  Evaluating the Safety and Efficacy of the AlphaVac Multipurpose 
Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute 
Pulmonary Embolism.  
Protocol Number:  2021 -EVT -01 
SAP Version/Date:  1.0, 07-Dec-2023  
We, the undersigned, have reviewed and approved this Statistical Analysis Plan:  
   
Signature   Date  
   
   
Md Nazir Uddin   
Biostatistician  
Medpace, Inc.    
   
   
Ariel Bloch    
Senior Data Scientist  
AngioDynamics , Inc.     
   
   
Liz Manning    
Director, Clinical Affairs  
AngioDynamics, Inc.    
  
Md Nazir UddinElectronically signed by: Md Nazir Uddin 
Reason: Approved 
Date: Dec 8, 2023 12:47 EST 
Electronically signed by: Ariel Bloch 
Reason: Approved 
Date: Dec 19, 2023 16:32 EST 
Electronically signed by: Liz Manning 
Reason: Approved 
Date: Dec 19, 2023 16:34 EST 
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 3 of 19 
 VERSION HISTORY  
 
Version  Version Date  Description  
1.0 07-Dec-2023  Original signed version  
   
   
  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 4 of 19 
 TABLE OF CONTENTS  
1 INTRODUCTION  ................................ ................................ ................................ ................................  7 
2 STUD Y DESIGN  ................................ ................................ ................................ ................................ . 7 
2.1 Study Description  ................................ ................................ ................................ ..........................  7 
2.2 Device Description  ................................ ................................ ................................ ........................  7 
2.3 Indication for Use  ................................ ................................ ................................ .........................  7 
2.4 Study Population  ................................ ................................ ................................ ...........................  7 
2.5 Study Enrollment  ................................ ................................ ................................ ..........................  7 
2.6 Enrollment Procedure  ................................ ................................ ................................ ...................  8 
2.7 Study Objective  ................................ ................................ ................................ .............................  8 
2.8 Study Procedure  ................................ ................................ ................................ ............................  8 
2.9 Adjunctive Treatment  ................................ ................................ ................................ ...................  8 
3 PRIMARY SAFETY AND EFFICACY  ................................ ................................ ..............................  8 
3.1 Primary Endpoints  ................................ ................................ ................................ ........................  8 
3.2 Seco ndary Endpoints  ................................ ................................ ................................ ....................  9 
3.3 Exploratory Endpoint  ................................ ................................ ................................ ....................  9 
4 STATISTICAL METHODOLOGY  ................................ ................................ ................................ ..... 9 
4.1 General Considerations  ................................ ................................ ................................ .................  9 
4.2 Determination of Sample Size  ................................ ................................ ................................ ...... 9 
4.3 Analysis Day  ................................ ................................ ................................ ...............................  11 
4.4 Analysis Visits  ................................ ................................ ................................ ............................  11 
4.5 Definitions of Baseline ................................ ................................ ................................ ................  11 
4.6 Summary Statistics  ................................ ................................ ................................ ......................  11 
4.7 Poolability of Data  ................................ ................................ ................................ ......................  11 
4.8 Handling Missing Data  ................................ ................................ ................................ ...............  12 
4.9 Analysis Populations  ................................ ................................ ................................ ...................  13 
4.9.1 As Treated Population  ................................ ................................ ................................ .........  13 
4.9.2  Modified As Treated Population  ................................ ................................ .........................  13 
4.9.3  Per Protocol Population  ................................ ................................ ................................ ...... 13 
4.10  Subject Data  ................................ ................................ ................................ ................................  13 
4.10.1  Subject Disposition  ................................ ................................ ................................ .............  13 
4.10.2  Protocol Deviations  ................................ ................................ ................................ .............  13 
4.10.3  Analysis Population  ................................ ................................ ................................ ............  13 
4.10.4  Demographic Characteristics  ................................ ................................ ..............................  13 
4.10.5  Medical History ................................ ................................ ................................ ...................  14 
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 5 of 19 
 4.10.6  Concomitant Medications  ................................ ................................ ................................ ... 14 
4.11  Efficacy and Safety Assessment  ................................ ................................ ................................ . 14 
4.11.1  Primary Efficacy Endpoints Analysis  ................................ ................................ .................  14 
4.11.2  Primary Safety Endpoint Analysis  ................................ ................................ ......................  14 
4.11.3  Secondary Efficacy Endpoint Analysis  ................................ ................................ ...............  15 
4.11.4  Secondary Safety Endpoint Analysis  ................................ ................................ ..................  15 
4.11.5  Subgroup Analysis  ................................ ................................ ................................ ..............  16 
4.11.6 Sensitivity Analysis ................................ ................................ ................................ .............  16 
4.12  Safety Assessment  ................................ ................................ ................................ ......................  17 
4.12.1  Adverse Events  ................................ ................................ ................................ ...................  17 
4.12.2  Serious Adverse Events  ................................ ................................ ................................ ...... 17 
4.12.3  Adverse Device Effects  ................................ ................................ ................................ ....... 18 
4.12.4  Unanticipated Adverse Device Effects (UADE)  ................................ ................................ . 18 
4.12.5  Adverse Event Severity  ................................ ................................ ................................ ....... 18 
4.12.6  Deaths  ................................ ................................ ................................ ................................ . 18 
4.12.7  Device Malfunctions  ................................ ................................ ................................ ...........  18 
4.13  Clinical Laboratory Tests  ................................ ................................ ................................ ............  18 
4.14  Vital Signs  ................................ ................................ ................................ ................................ ... 18 
5 INTERIM ANALYSIS  ................................ ................................ ................................ .......................  18 
6 DATA MON ITORING COMMITTEE  ................................ ................................ ..............................  19 
7 CLINICAL ENDPOINT COMMITTEE  ................................ ................................ ............................  19 
8 END OF STUDY ANALYSIS  ................................ ................................ ................................ ...........  19 
9 CHANGE FROM PROTOCOL -SPECIFIED STATISTICAL ANALYSIS  ................................ ..... 19 
10 PROGRAMMING SPECIFICATION  ................................ ................................ ................................  19 
 
 
 
  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 6 of 19 
 LIST OF ABBREVIATIONS  
Abbreviation  Definition  
AHC  Accountable Health Communities  
ATC  Anatomical Therapeutic Chemical  
ADE  Adverse Device Effects  
ADAM  Analysis Data Model  
AE  Adverse Event  
CSR  Clinical Study Report  
CTA  Computed Tomography Angiography  
EDC  Electronic Data Capture  
eCRF  Electronic Case Report Form  
HRSN  Health - related Social Needs Screening Tool  
ICU Intensive Care Unit  
LV Left Ventricle  
MedDRA  Medical Dictionary for Regulatory Activities  
MMA  Multipurpose Mechanical Aspiration  
MAE  Major Adverse Event  
PE Pulmonary Embolism  
RCT  Randomized Control Trial  
RV Right Ventricle  
SAP  Statistical Analysis Plan  
SAE  Serious Adverse Event  
SD Standard Deviation  
SDV  Source Data Verification  
SDTM  Study Data Tabulation Model  
TFL Tables, Figures, and Listings  
UADE  Unanticipated Adverse Device Effect  
  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 7 of 19 
  
1 INTRODUCTION   
The purpose of this Statistical Analysis Plan (SAP) is to provide a description of the statistical methods to 
be implemented for the analysis of data from the AngioDynamics protocol 2021 -EVT -01, “Evaluating the 
Safety and Efficacy of the AlphaVac Multipurp ose Mechanical Aspiration (MMA) F1885 PE for Treatment 
of Acute Pulmonary Embolism.” If circumstances arise during the study such that more appropriate analytic 
procedures become available, the SAP may be revised. The SAP will be finalized prior to databas e lock. 
Any deviations from the SAP after database lock will be documented in the final Clinical Study Report 
(CSR).   
2 STUDY DESIGN  
2.1 Study Description  
This is a prospective, multicenter, single arm study. This study will include up to 122 patients at up to 30 
centers in the United States. Each subject will be in the trial for approximately 30 days.  
2.2 Device Description  
The AngioDynamics’ AlphaVac MMA  F1885 PE has five main components, a flexible cannula (F1885), 
sheath, tapered obturator, aspirator handle, and waste bag. The AlphaVac MMA F1885 PE is a mechanical 
aspiration thrombectomy device with a nitinol basket reinforced, self -expandable funnel shaped d istal tip, 
that is collapsed using an over -sheath that is advanced though a 22 Fr sheath and over a guidewire into the 
venous system percutaneously.  
2.3 Indication for Use  
The AlphaVac MMA F1885 PE System is a commercially available device (marketed under K213388). At 
present, the device is not cleared for the specific submassive acute PE indication for which it is being tested.  
Current Indication:  
The Cannula is indicated for : 
• The non -surgical r emoval of thrombi or emboli from venous vasculature.  
• Aspiration of contrast media and other fluids from venous vasculature.  
The Cannula is intended for use in the venous system.  
The Handle is indicated as a vacuum source for the AlphaVac MMA System . 
During use the cannula is placed within the jugular or one of the common femoral veins and connected to 
the aspirator handle. Once access is gained, the cannula is advanced under image guidance towards the 
undesirable intravascular (i.e., thrombus or emboli) until it is engaged, the aspirator is then pulled back 
creating suction pulling the material into the cannula, removing it from the vasculature. The aspirated 
material is then moved from the aspiration handle into the waste bag for disposal.  
2.4 Study Populati on   
This study will collect data on symptomatic patients with acute intermediate -risk PE. The enrolled patients 
will be treated with aspiration thrombectomy by the AlphaVac MMA F1885 PE. 
2.5 Study Enrollment    
Patients presenting with signs and symptoms of a cute intermediate risk PE will be screened for possible 
enrollment as a patient into the trial based on Inclusion/Exclusion Criteria.  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 8 of 19 
 2.6 Enrollment Procedure  
Consecutive patients presenting with acute intermediate -risk PE will be screened for this trial. Tho se who 
do not meet the study’s Inclusion/Exclusion Criteria will not be enrolled with the reason recorded.  
A patient is considered enrolled once the patient informed consent form and HIPAA Authorization are 
signed by the patient, and in whom the AlphaVac M MA F1885 PE has been introduced into their body.  
Any patient enrolled into the trial, but in whom the AlphaVac MMA F1885 PE is not able to access a 
pulmonary embolus is considered an as treated patient and will be monitored per protocol until the end of 
required follow -up period of 30 days.  
Any patient that experiences an adverse event after venous puncture but in whom the Cannula is not inserted 
will be monitored through discharge for safety.  
2.7 Study Objective   
The objective of this clinical study is to d etermine the safety and effectiveness of mechanical aspiration 
thrombectomy using the AlphaVac MMA F1885 PE in a prospective trial of patients with acute 
intermediate -risk PE.  
2.8 Study Procedure  
All data elements for all subjects will be collected using elect ronic case report forms (eCRFs). Source data 
originally captured in electronic format may be used to populate eCRF data fields where possible to reduce 
unnecessary duplication of data and to reduce the possibility of transcription errors. Data will be ente red 
into the eCRFs at screening, baseline/index procedure, at 48 -Hours, discharge, and at 30 -days post 
procedure or until death, and in accordance with the adverse event procedures described below. Sites will 
be requested to adhere to guidelines for the treatment and monitoring of these subjects. Planned Source 
Data Ver ification (SDV) will be 100% for all endpoint -related data.  
2.9 Adju nctive  Treatment  
There may be circumstances for the need to use other treatments to aid the AlphaVac MMA  F1885 PE in 
recanalizing the targeted vessel. Adjunctive treatments will be considered as a protocol deviation unless 
used to treat clinical deterioration. These adjunctive treatments will be recorded on the CRF.  
3 PRIMARY SAFETY AND EFFICACY  
3.1 Primary Endpoints  
 Outcome  
Primary Efficacy:  Reduction in the right ventricle (RV)/left ventricle ( LV) ratio at 48 hours post -
procedure assessed by computed tomography angiography (CTA ). The 
primary efficacy analysis will be the difference between the baseline and the 
48-hour RV/LV diameter ratio.  
Primary Safety:  Rate of major adverse events post -procedure, defined as:  
• Device -related death within 48 hours  
• Major bleeding within 48 hours  
• Device -related serious adverse events ( SAEs ) within 48 hours,  which 
includes:  
o Clinical deterioration  
o Pulmonary vascular injury  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 9 of 19 
 o Cardiac injury  
Some examples of major bleeding, clinical deterioration, pulmonary vascular 
injury, and cardiac injury are defined in the study definitions of Appendix I of 
the protocol.  
 
3.2 Secondary Endpoints  
  
Outcome  
Secondary  Efficacy:  • Length  of stay in intensive care unit  (ICU)/Hospital  setting  within  
30 days 
• Use of thrombolytics  within  48 hours  
• Change in Modified Miller Index at 48 hours post -procedure 
assessed by CTA  
Secondary  Safety:  
 • Device -related  death  within  48 hours  
• Major  bleeding  within  48 hours  
• Clinical  deterioration  within  48 hours  
• Pulmonary  vascular  injury  within  48 hours  
• Cardiac  injury  within  48 hours  
• Any-cause  mortality  within  30 days 
• Device -related  SAEs  within  30 days 
• Symptomatic  PE recurrence  within  30 days 
Refer  to Appendix  I of the protocol for definitions.  
3.3 Expl oratory  Endpoint  
This study will collect baseline data to identify unmet social related needs such as housing instability, 
violence, financial strain, etc. Exploratory analysis may be conducted to evaluate healthcare disparities, 
unmet healthcare needs with study enrollments and outcomes.  Specifically, a linear regression model will 
be generated to assess if the n umber of unmet healthcare needs has an impact on the primary efficacy 
endpoint, namely the change in RV/LV ratio between Screening and 48 Hours Post Procedure.  
The accountable health communities (AHC) health -related social needs screening tool (HRSN) will be 
completed by all enrolled patients at their baseline visit.  
4 STATISTICAL METHODOLOGY  
4.1 General Considerations  
Standard statistical methods will be employed to analyze all data. All data collected in this study will be 
documented using summary tables and patient data listings. Continuous variables will be summarized using 
descriptive statistics, including counts, mean, median, standard deviation (SD), minimum and maximum. 
Where appropriate, 95% two -sided confidence intervals for the means will be prese nted. Categorical 
variables will be summarized by frequencies and percentages. Unless explicitly stated otherwise, 
percentages will utilize a denominator corresponding to the number of unique patients.  
4.2 Determination of Sample Size  
This study is designed t o assess the efficacy of the AlphaVac  MMA F1885 PE with respect to the primary 
efficacy endpoint (reduction in RV/LV ratio between baseline and 48 hours post procedure) as well as to 
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 10 of 19 
 assess the safety of the AlphaVac MMA F1885 PE with respect to the primar y safety endpoint (rate of any 
major adverse event ( MAE ) within 48 hours of the procedure).  
The safety performance goal is that less than 25% of study subjects experience an MAE (the primary safety 
endpoint)  within 48 hours after the index procedure.  This is based on the upper limit of the 95% confidence 
interval for the average composite MAE rate (16.3%) observed across 7 randomized control trials ( RCTs ) 
in which acute PE was treated with thrombolysis versus an anticoagulant control. For this study, the 
hypothesized composite MAE rate is expected to be approximately 15%. To detect a difference between an 
expected MAE rate of 15% and the performance goal of 25% with 80% power, the necessary sample size 
was calculated to be 103 (with a one -sided p -value = 0.0 5). A sample size of 103 patients was selected as a 
conservative sample size to assess safety with adequate statistical power. To account for attrition rate of 
15%, 122 subjects will be enrolled.  
Sample size determination - Safety:  
 
Endpoint  Primary Analys is 
Population  Assumed Performance of  
Manual Mechanical  
Aspiration Catheter  Performance  
Goal  Power  Sample  
Size 
Rate of 
Any MAE  As Treated  15% 25% 80% 103 
The SAS code for safety sample size calculation is included below:  
proc power ; 
onesamplefreq test = z method = normal  
sides = 1 
alpha = 0.05 
nullproportion = 0.25 
proportion = 0.15 
ntotal = . 
power = .80; 
run; 
The efficacy performance goal of 0.12mm reduction in the RV/LV ratio from baseline was calculated using 
4 randomized controlled trials that discuss the treatment of acute PE with anticoagulants, which is standard 
of care. The mean decrease in RV/LV ratio a cross the 4 trials was 0.12mm. A standard deviation of 0.25mm 
was based on the standard deviation of the RV/LV ratio observed in the FLARE trial.  
Sample size determination – Efficacy:  
 
Endpoint  Primary 
Analysis  
Population  Assumed 
Performance of  
Manual Mechanical  
Aspiration Catheter  Assumed 
Standard 
Deviation  Performance  
Goal  Power  Sample  
Size 
Reduction 
in 
RV/LV 
Ratio  Modified as  
treated  0.20 0.25 0.12 80% 62 
 
The SAS code for safety sample size calculation is included below:  
proc power ; 
pairedmeans sides = U 
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 11 of 19 
 test = diff  
nulldiff = 0.12 
meandiff = 0.20 
power = 0.8 
corr = 0.5 
npairs = . 
std = 0.25; 
run; 
 
4.3 Analysis Day  
Analysis day will be calculated from the date of the first index procedure. The day of the index procedure 
will be Day 1 and the day immediately before Day 1 will be Day -1. There will be no Day 0 . 
4.4 Analysis Visits  
Scheduled visits will be assigned to analysis visits as recorded on the eCRF.  There are five visits considered 
for this study : Screening, Baseline/Index Procedure , 48-Hours Post-Procedure, Discharge, and 30 Day 
Follow -Up. Any unscheduled visits will not be considered for the summary statistics but will be included 
in listings.  
4.5 Definitions of Baseline  
Baseline is defined as the last assessment obtained prior to  the index procedure.  
4.6 Summary Statistics  
For tables, categorica l data will generally be summarized with counts and percentages of participants. The 
denominator used for the percentage calculation will be clearly defined. Continuous data will generally be 
summarized with descriptive statistics including n (number of no n-missing values), mean, median, SD, 
minimum, and maximum.   
In summary tables, data from the scheduled visits, including conditional follow -up visits, will be included.   
Listings will include all data from scheduled and unscheduled/ End of Study visits an d will serve as  data 
sources for all tables and figures.     
4.7 Poolability of Data  
This study is designed and conducted as a multicenter clinical trial. All participating sites will be selected 
using the same criteria and trained prior to enrolling subjects. All subjects will be treated and evaluated 
following the same protocol to ensure generalizability of the study results. Poolability of the data across 
centers in a multicenter study is assumed without burden of proof.  
Nevertheless, poolability of data acro ss sites will be examined for apparent violation of the poolability 
assumption.  
A logistic regression on the primary safety endpoint and a linear regression on the primary efficacy endpoint 
will be used to confirm the pooling of data across sites. For each regression model, a test for fixed site effect 
at the 0.15 alpha level will be used to assess potential heterogeneity. If there is evidence of heterogeneity 
of sites, a random site -effect model will be used to summarize the associated endpoint. The results of the 
poolability analysis will be used to assess the robustness of study res ults, not to change the study conclusion. 
Sites with fewer than five subjects will be combined and treated as a single site for these analyses.  
Sample SAS code for the logistic regression can be found below: 
/*****************************  
MAEDATA is the da ta set that includes MAE as a binary response variable and  
SITE as a categorical predictor variable.  
 
MAE=1,if the subject experienced an MAE  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 12 of 19 
 MAE=0, otherwise  
SITE=Study site  
******************************/  
proc logistic  data = MAEDATA;  
class SITE; 
model MAE = SITE; 
run;  
 
The effect of AHC -HRSN will be evaluated through a simple linear regression model. The AHC -HRSN 
score will be calculated by following the AHC -HRSN manual and will be equivalent to the number of 
domains in which the subject h as an unmet health -related social need.  
 
Sample SAS code for the linear regression can be found below:  
/******************************  
RVLVDATA is the data set that includes RVLVCHG, a variable representing the 
change in RV/LV ratio, and SITE as a categorical predictor variable.  
  
RVLVCHG=Change in RV/LV ratio at 48 hours post procedure from baseline  
SITE=Study site  
AHC_HRSN=1, if subject's AHC -HRSN score > median score  
AHC_HRSN=0, if subject's AHC -HRSN score ≤ median score  
*********************** *******/  
PROC GLM DATA = RVLVDATA ; 
  CLASS SITE; 
  MODEL RVLVCHG = SITE AHC_HSRN;  
  RUN; 
 
4.8 Handling Missing Data  
Missing data are defined as data that are expected to be collected but are not available for the study at the 
time of the final analysis. In this study, missing data will not be imputed nor handled with the last 
observation carried forward. In general, data will be analyzed as they are recorded with the following 
specific methods apply to defining and handling missing data.  
• Patient s who drop out before study completion will not be replaced and all information obtained 
from them will be included in the analysis.  
• Missed visits: If a patient missed a visit, information to be collected during that visit is considered 
as missing data . Patients with a missing visit will be removed from the analysis for that visit. For 
example, subjects without a 30 -Day follow -up visit will not be included in the analysis of the 
symptomatic PE recurrence secondary endpoint.  
• Missing Data: We expect relativel y few patients to be missing the primary endpoints due to 
withdrawal or refusal due to the short study f ollow-up period. The Electronic Data Capture (EDC) 
supports efficient data collection and management and facilitates rapid data closure. The frequency 
of missing data can be reduced by two mechanisms: the coordinators will receive a list of queries 
generated by the study monitors upon logging into the system, and any data required during a visit 
is immediately evident through the system and can be collect ed before closure of the visit window. 
Despite the screening and ongoing communication with patients regarding the importance of study 
endpoint assessment, we anticipate no more than 15 % of subjects will be missing primary endpoint 
assessments due to tech nical issues/low -quality of the diagnostic pulmonary CTA images, 
procedural mortality, withdrawal, or refusal to continue participation in the study or lost to follow -
up. Patients missing primary endpoint assessments due to lost to follow -up are accounted for in the 
sample size calculation.  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 13 of 19 
 4.9 Analysis Populations  
4.9.1 As Treated Population  
The As Treated population includes all subjects who met the inclusion/exclusion criteria and in whom the 
F1885 cannula is placed within the jugular or one of the common femoral veins. This population will serve 
as the primary analysis set for all safety endpoints and supportive analysis set for all efficacy endpoints.  
4.9.2 Modified As Treated Population  
The Modified a s Treated population includes all subjects in the as treated population who did not receive 
thrombolytics during the index procedure. This population will be used as the primary analysis set for all 
efficacy endpoints.  
4.9.3 Per Protocol Population  
Per Protocol  population includes all subjects in the Modified As Treated population who had no major 
protocol deviations.  This population will serve as a supportive analysis cohort for all efficacy endpoints.  
4.10 Subject Data  
4.10.1  Subject Disposition  
Counts and percentages of  participants who completed the study, discontinued from the study along with 
the reason for discontinuation from study will be summarized  for all population as defined in Section 4.9 . 
A by -participant listing will be provided.  
4.10.2  Protocol Deviations  
Protocol deviations will be identified based on the clinical data as defined in the Protocol Deviation Plan. 
The Protocol Deviation Plan will define all protocol deviations as either major  or minor  deviations. Patients 
with protocol deviations will be summarized in a table by deviation category and deviation type as well as 
in data listings. All enrolled patients will be included in the reporting of protocol deviations.  The 
summarization will be rep eated for all population as defined in Section 4.9 . 
4.10.3  Analysis Population  
Counts and percentages of subjects in each analysis population will be summarized.  
4.10.4  Demographic Characteristics  
The following demographic characteristics will be summarized:  
• Age (years)  
• Gender  
• Race  
• Ethnicity  
• Smoking status  
• Year of smoking  
• Cigarettes/day  
Demographic information will be summarized with descriptive statistics or counts  and percentages of 
subjects,  as appropriate  for all population defined in Section 4.9 . 
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 14 of 19 
 4.10.5  Medical History  
Counts and percentages of participants with relevant medical history will be summarized by category and 
condition based on the as treated population. In addition, all other medical history will be summarized by 
system organ class and preferred term using the  Medical Dictionary for Regulatory Activities (MedDRA) 
version 25.0. Participants will be counted only once for each system organ class and preferred term level.  
The summarization will be repeated for all population as defined in Section 4.9 . 
4.10.6  Concomitant Medications  
Concomitant medications are defined as any medication that was used at least once after the administration 
of the study device. Medications that were stopped on the same date as the administration of the study 
device  will be analyze d as concomitant medications.   
Concomitant medications will be coded to anatomical therapeutic chemical (ATC) class and preferred term 
using the WHO Drug B3. 
Counts and percentages of participants taking concomitant medications by ATC class and preferred term 
will be summarized using  the as treated population. Participants who used the same medication on multiple 
occasions will only be counted once in the specific category (preferred term).  The summarization will be 
repeated for all population as defined i n Section 4.9 .     
4.11 Efficacy  and Safety Assessment  
The analysis for all efficacy endpoints will be performed based on the Modified As Treated population. 
Supportive analysis for all efficacy endpoints will be performed based on the As Treated population and  
the Per Protocol population. The analysis for all safety endpoints will be performed based on the As Treated 
population.  
4.11.1  Primary Efficacy Endpoints Analysis  
The primary efficacy analysis will be the reduction in the RV/LV ratio between Baseline and 48 hours post 
procedure. The mean reduction in the RV/LV ratio will be compared to a performance goal of 0.12 mm. 
The hypothesis for reduction from baseline in RV/LV ratio is as follows:  
𝐻0:𝑅𝑑𝑖𝑓𝑓<0.12 
𝐻1:𝑅𝑑𝑖𝑓𝑓≥0.12 
Where, 𝑅𝑑𝑖𝑓𝑓 is the mean reduction in the RV/LV ratio between Baseline and 48 hours post procedure. 
The mean reduction in the RV/LV ratio will be compared to the performance goal of 0.12 mm using a 
paired samples t -test with a significance level of 0.05.  
Sample SAS code for the paired sample t -test can be found below:  
/****************************************  
Note: 
BASE=RV/LV ratio at basel ine 
POSTHRS=RV/LV ratio at 48 hours post baseline  
*******************************************/  
proc ttest data=RVLVDATA sides=u alpha=0.05 h0=0.12; 
 title "Paired sample t -test"; 
 paired BASE * POSTHRS;  
   run; 
4.11.2  Primary Safety Endpoint Analysis  
The primary safety analysis will be the rate of any MAE within the first 48 hours after the index procedure.   
MAEs are defined as:  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 15 of 19 
 • Device -related death  
• Major bleeding  
• Device -related serious clinical deterioration  
• Device -related serious pulmonary vascular injur y 
• Device -related serious cardiac injury  
Examples of major bleeding, clinical deterioration, pulmonary vascular injury, and cardiac injury are 
defined in Appendix I of the protocol.  
The proportion of subjects who experienced any MAE within 48 hours will be compared to a performance 
goal of 25%. The hypothesis for the rate of any MAE is as follows:  
𝐻0:𝑀𝐴𝐸>0.25 
𝐻1:𝑀𝐴𝐸≤0.25 
Where MAE is the proportion of subjects who experienced any MAE within 48 hours of the procedure.  
The rate of any MAE within 48 hours of the procedure will be compared to the performance goal of 25% 
using a one sample proportion test with a significance level of 0.05.  
 
Sample SAS code for one sample proportion test can be found below:  
/****************************************  
Note: 
IMAE=’Yes’ if subject had an MAE  
IMAE=’No’ No MAE  
*******************************************/  
proc freq data=MAEDATA;  
 tables IMAE / binomial( p=0.25 level="Yes"); 
run; 
4.11.3  Secondary Efficacy Endpoint Analysis  
The secondary efficacy endpoints will include the following:  
1. Length of stay in ICU/Hospital setting within 30 days 
2. Use of thrombolytic within 48 hours of the index procedure  
3. Change in Modified Miller Index between baseline and 48 hours of the index procedure  
Length of stay in the ICU/Hospital setting within 30 days and the change in Modified Miller Index will be 
summarized descriptively. Point estimates will be reported. For all other secondary efficacy endpoints, the 
number and proportion of patients who experienced each endpoint will be presented.   
4.11.4  Secondary Safety Endpoint Analysis  
1. Major bleeding within 48 hours  
2. Device -related death within 48 hours  
3. Device -related clinical deterioration within 48 hours  
4. Device -related pulmonary vascular injury within 48 hours  
5. Device -related cardiac injury within 48 hours  
6. Any-cause mortality within 30 days  
7. Device -related serious adverse events within 30 days  
4. Symptomatic recurrence of PE at 30 days (Recurrent pulmonary embolism is defined in the Study 
Definitions of Appendix I of protocol).  
The number and proportion of patients who experienced each of the secondary safety endpoints will be 
presented.  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 16 of 19 
 4.11.5  Subgroup Analysis  
Subgroup analyses are exploratory in nature and may include demographic information, baseline 
characteristics, and other factors to be determined after the study team reviews the final analyses of primary 
and secondary endpoints.  
4.11.6  Sensitivity Analysis  
Sensitivity analyses may be performed on the primary eff icacy and primary safety endpoints to describe 
the potential impact of missing data on the observed study results. Subjects missing the primary efficacy 
endpoint and/or primary safety endpoint will be imputed using best -case and worst -case analyses. For 
subjects missing the primary efficacy endpoint, best -case imputation will use the best observed change in 
RV/LV ratio at 48 hours post procedure in the study population. Worst -case imputation of the primary 
efficacy endpoint will use the worst observed chang e in RV/LV ratio at 48 hours post procedure in the study 
population. For subjects missing the primary safety endpoint, best -case imputation will assume the subject 
did not experience an MAE within the first 48 hours after the procedure. Worst -case imputati on of the 
primary safety endpoint will assume the subject did experience an MAE within the first 48 hours after the 
procedure.  
Further, a tipping point analysis may be performed to assess sensitivity without need for postulating a 
specific set of assumpti ons regarding missing data.  Missing data for the RV/LV ratio will be imputed for 
the primary efficacy  analysis  using  multiple imputation methodology in two steps . Initially, 25 data sets 
will be imputed for non-monotone missing values in the original datas et. In the second step, the remaining 
monotone missing values will be imputed.  Generally, the number  of imputations should be at least as much 
as the percentage of cases that are incomplete. Therefore, twenty -five imputations were selected for the  
primary analysis. Upon completion of the trial, if the percentage of cases with incomplete data is  larger 
than initially anticipated then the number of imputations will be increased for the final  analysis.  
The variable for the imputation model will consist  of the RV/LV ratio at  Baseline. For each imputation  
dataset, the mean reduction in the RV/LV ratio between Baseline and 48 hours post procedure  will be 
analyzed using the paired t -test model  described above. The results from these 25 analyses will be comb ined 
to construct the  mean estimates using the parameter estimates and associated standard errors. The combined 
parameter estimates will  then be used to test the hypothesis for the reduction from baseline in RV/LV ratio 
as described above (meaning, against  a hypothesis test cut -off value of 0.12) . Randomly chosen seed  
numbers will be selected for the analysis and will be retained.  
The analysis will be performed using a tipping point approach under the missing not at random assumption 
by adding a shift (delta) to the RV/LV ratio at 48 hours post procedure . The delta values will range from  -1.0 
to 1.0 by 0. 05 increments. If the tipping point (i.e., delta  value for which statistical significance is lost) is 
outside of this range, it will be extended to the  value at which statistical significance is lost , as appropriate . 
Example SAS® code for  performing this analysis is as follows:  
/****************************************  
Multiple Imputation for Non-Monotone missing values  
Assuming a shift of 0.00 that will be adjusted up or down during the tipping 
point analysis  
Note: 
BASE=RV/LV ratio at baseline  
POSTHRS=RV/LV ratio at 48 hours post baseline  
*******************************************/  
proc mi data=RVLV_temp seed=12141619  out=data_imp MCMC nimpute=25; 
   var BASE POSTHRS;  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 17 of 19 
    mcmc impute=monotone chain=single; 
run; 
proc mi data=data_impMCMC seed=07071107  out=data_impMONO nimpute=1 simple; 
   by _Imputation_;  
   monotone  reg; 
   var BASE POSTHRS;  
   mnar adjust (POSTHRS / shift= 0.00); 
run; 
 
/****************************************  
Paired T -test 
*******************************************/  
ods select none; 
proc ttest data= data_imp MONO sides=u alpha=0.05; 
 by  _Imputation_ ;  
    paired BASE * POSTHRS;  
    ods output Statistics = ttest_parms;  
run; 
ods select all; 
 
/****************************************  
MIANALYZE to combine results of imputed data sets  
*******************************************/  
proc mianalyze  data=ttest_parms  theta0=0.12; 
   modeleffects  mean; 
   STDERR stderr; 
   ods output ParameterEstimates = mi_parms;  
run; 
If there is evidence of non -normality of the primary efficacy endpoint based on a Shapiro -Wilk test at the 
0.05 alpha level, a non -parametric sign test will be used.  
4.12 Safety Assessment  
4.12.1  Adverse Events  
An adverse event (AE) is any untoward medical occurrence, unintended disease or injury or any untoward 
clinical signs in subjects whether or not related to the Investigational Product and includes events related 
to the procedures involved (any procedure in  the clinical investigation plan). Safety events will refer to all 
peri procedural MAEs, serious AEs (SAEs), Major AEs (MAEs), adverse device effects (ADEs) (including 
serious adverse device effects [SADEs]), and (severe) unanticipated adverse device effec ts 
(UADEs/SUADEs). A detail ed description of the how AEs are identified and reported  can be found in 
Section 10.1 in the protocol.  
All adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA). 
The number and perce nt of subjects in the  As Treated population who experience each AE will be 
summarized by MedDRA system organ class and preferred terms. Adverse events will also be presented in 
by-participant  listing s.  
4.12.2  Serious Adverse Events  
 Serious AEs are a subset of A Es. An SAE is one that:  
1. Results in death  
2. Results in life -threatening illness or injury  
3. Results in a permanent impairment of a body structure or function  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 18 of 19 
 4. Requires inpatient hospitalization or prolongation of an existing hospitalization  
5. Results in a medical or surgical intervention in order to prevent a permanent impairment to a 
body structure or function, or  
6.  Results in fetal distress, fetal death, or a congenital abnormality or birth defect  
7. Important medical event  
4.12.3  Adverse Devi ce Effect s  
Adverse device effects (ADEs) are a subset of adverse events. The ADEs are AEs caused by or related to 
thrombectomy procedure performed by the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 
PE (possibly, probably and definitely related), includ ing any AE resulting  in a malfunction of the AlphaVac 
Multipurpose Mechanical Aspiration (MMA) F1885 PE or any event that is a result of a use error or 
intentional misuse. With any procedure or treatment, there are known possible risks and complications. 
With the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE, all risks known for the 
proposed indication can be found in Section 10.11 of the protocol. A list of precautions and warning s 
concerning the use of the device is found in the device’s IFU.  
4.12.4  Unanticipated Adverse Device Effects (UADE)  
Overall summary statistics and by participant listings will be provided.   
4.12.5  Adverse Event Severity   
Overall summary statistics and by participants listings will be provided for all adverse event s by maximum 
severity . 
4.12.6  Death s  
Overall summary statistics and by participants listings will be provided for all death s. 
4.12.7  Device Malfunction s  
Overall summary stati stics and by participants listings will be provided for all device malfunction s.  
4.13 Clinical Laboratory Tests  
Results of clinical laboratory tests will be descriptively summarized . Laboratory test results  at each 
scheduled visit a s well as  changes from baseline for each test  will be displayed . Shift tables showing the 
categorical results at baseline and 48 hours post procedure will also be provided.  
By-participant listings will be provided  by clinical laboratory test, and values outside th e reference ranges 
will be flagged.     
4.14 Vital Signs  
Vital sign parameters including height, weight, body mass index (BMI), blood pressure, shock index, 
heart rate, respiratory rate, body temperature, oxygen saturation, and FiO2 will be summarized 
descripti vely.  
By-participant listings will also be provided.  
5 INTERIM ANALYSIS  
There are no planned interim analyses for the purposes of early stopping for success, sample size 
modification, or other trial design changes. Analyses of accruing data for regulatory submissions in 
different geographies may be performed at different points during the study. These analyses are only 
intended to support geographic specific regulatory requirements. Since there is no planned early stopping 
or sample size adjustme nt planned, there are no type I error concerns.  
AngioDynamics, Inc.  CONFIDENTIAL  Statistical Analysis Plan  
2021 -EVT -01     Version 1.0, 07 Dec 2023  
 
Page 19 of 19 
 To protect against the introduction of operational bias, distribution of aggregate results from such analyses 
will be restricted on a “need -to-know” basis. Access to aggregate results will be restricted to th ose persons 
necessary to complete the associated regulatory submission. Aggregate results will specifically not be 
provided to study sites, investigators, or staff or to those involved with the management of the study.  
6 DATA MONITORING COMMITTEE  
A data moni toring committee (DMC) will be established to review cumulative study data to evaluate safety 
(interim and cumulative data for AEs), study conduct, and scientific validity and integrity of the trial. The 
DMC will consist of at least 3 independent subject m atter experts who will be voting members and a 
Statistician (voting or non -voting). The three voting members will be physicians not associated with the 
study in any capacity or have any affiliations with the study sponsor or sponsor’s designee, and without  any 
direct business associations with the principal investigator of the trial. The physicians may be selected from 
different disciplines but with an understanding of the study population and procedures. None of the 
members will have direct involvement in the conduct of the study or have any conflict of interests. The 
initial DMC meeting will develop the DMC Charter which will contain operational details including 
schedule for meetings, triggers set for data review or analyses, definition of a quorum, and s topping rules 
for safety.  
The conduct of the DMC will be guided by the Food and Drug Administration guidance on the 
“Establishment and Operation of Clinical Trial Data Monitoring Committees for Clinical Trial Sponsors.” 
The decision to implement the recomm endations of the DMC will be made by the Sponsor, following 
consultation with the coordinating Investigator(s).  
7 CLINICAL ENDPOINT COMMITTEE  
An independent CEC will be established for the purpose of reviewing clinical endpoints including safety 
and/or effec tiveness data. The CEC will consist of medical doctors who will not have direct involvement 
of the conduct of the study. The CEC will meet regularly to review and adjudicate appropriate adverse 
events for causality and attribution.  
8 END OF STUDY ANALYSIS  
Upon completion of the study, the database will be locked, and the final analysis will be generated. The end 
of study analysis will be performed on all available efficacy and safety data as described in the above 
sections of the SAP. In addition to TFLs, s tandard data tabulation model (SDTM) data and ADaM data 
along with associated files will be provided. Associated files may include the following: annotated case 
report forms (CRFs), SDTM specifications, SDTM programs, ADaM specifications, analysis data mod el 
(ADaM) programs, TFL programs, and CDISC Define packages for both SDTM and ADaM data.  
The result s of this analysis will be used for the CSR .   
9 CHANGE FROM PROTOCOL -SPECIFIED STATISTICAL ANALYSIS  
This SAP does not deviate from the statistical analysis d escribed in v 5.1 of the protocol. Any deviations 
from the protocol or SAP will be described in the CSR.  
10 PROGRAMMING SPECIFICATION  
Analyses will be performed using SAS® version 9.4 or higher.  
All available data will be presented in participant data listin gs which will be sorted by participant and visit 
date as applicable.  Detailed programming specifications will be provided in the separate documents.  